

RESEARCH

Open Access

# Dynamic gene expressions of peripheral blood mononuclear cells in patients with acute exacerbation of chronic obstructive pulmonary disease: a preliminary study

Xiaodan Wu<sup>1†</sup>, Xiaoru Sun<sup>2†</sup>, Chengshui Chen<sup>2\*</sup>, Chunxue Bai<sup>3</sup> and Xiangdong Wang<sup>2,3\*</sup>

## Abstract

**Introduction:** Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a serious event that is responsible for the progress of the disease, increases in medical costs and high mortality.

**Methods:** The aim of the present study was to identify AECOPD-specific biomarkers by evaluating the dynamic gene expression profiling of peripheral blood mononuclear cells (PBMCs) from patients with AECOPD on days 1, 3 and 10 after hospital admission and to compare the derived data with data from healthy controls or patients with stable COPD.

**Results:** We found that 14 genes were co-differentially upregulated and 2 downregulated greater than 10-fold in patients with COPD or AECOPD compared with the healthy individuals. Eight co-differentially upregulated genes and six downregulated genes were identified as a panel of AECOPD-specific genes. Downregulation of *TCF7* in PBMCs was found to be associated with the severity of COPD. Dynamic changes of Aminolevulinic acid synthase 2 and carbonic anhydrase I had similar patterns of Digital Evaluation Score System scores and may serve as potential genes of interest during the course of AECOPD.

**Conclusion:** Thus, our findings indicate a panel of altered gene expression patterns in PBMCs that can be used as AECOPD-specific dynamic biomarkers to monitor the course of AECOPD.

## Introduction

Chronic obstructive pulmonary disease (COPD) is an inflammation-based syndrome characterized by progressive deterioration of pulmonary function and increasing airway obstruction [1]. COPD is a major and growing public health burden, ranking as the fourth leading cause of death in the world [2]. In China, it is the fourth leading cause of mortality in urban areas and the third leading cause in rural areas [3]. Patients with COPD often experience a sudden deterioration, termed *acute exacerbations* of chronic obstructive pulmonary disease (AECOPD),

along with a progressive decline in lung function; AECOPD becomes more frequent and severe when the severity of disease increases [4,5]. There is a great need for early and sensitive diagnosis and novel therapeutic targets for the disease, especially for patients with AECOPD in whom COPD is diagnosed in the late phase of disease, when they have significant or irreversible impairment [6].

The progress of COPD is accelerated by the occurrence of the exacerbation induced by multiple factors, including infection. AECOPD is a serious event that is related to decreased health status, increased medical and social costs and increased mortality [7]. Inflammatory cells (for example, lymphocytes, monocytes or macrophages, and their products) could interact with each other or with structural cells in the airways and the lung parenchymal and pulmonary vasculature, leading to the worsening of COPD [8]. Increased numbers of CD8+ lymphocytes were suggested as one of COPD's characteristics, being present only in smokers who develop the disease [9]. Increased

\* Correspondence: chenchengshui@gmail.com; xiangdong.wang@clintransmed.org

<sup>†</sup>Equal contributors

<sup>2</sup>Department of Respiratory Medicine, Wenzhou Medical University and The First Hospital, Nanbaixiang, 325000, Wenzhou, China

<sup>3</sup>Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai Respiratory Research Medicine, Fenglin Rd. No 180, 200032, Shanghai, China

Full list of author information is available at the end of the article


pulmonary inflammatory mediators in patients with COPD could attract inflammatory cells from the circulation, amplify the inflammatory process and induce structural changes [9].

Peripheral blood mononuclear cells (PBMCs) act as a critical component in the immune system to fight infection and adapt to intruders and play an important role in the development of AECOPD. Gene expression profiles of PBMCs were found to be disease-specific and associated with severity [10]. PBMC samples were suggested as easy to gather and important to the discovery of biomarkers for diagnosis and therapeutic management of COPD [11,12], although gene expression changes in lung tissues were noted to be associated with COPD [13-15]. The aim of the present study was to determine AECOPD-specific biomarkers of PBMCs using the concept of clinical bioinformatics and integrating genomics, bioinformatics, clinical informatics and systems biology [16-18]. We translated all clinical measures, including patient complaints, history, therapies, clinical symptoms and signs, physician's examinations, biochemical analyses, imaging profiles, pathologies and other measurements, into digital format using a digital evaluation scoring system. PBMCs were isolated from healthy volunteers and patients with stable COPD or AECOPD, and we investigated the disease specificity that we inferred from clinical informatics analysis to search for COPD- or AECOPD-specific genes and dynamic biomarkers for AECOPD.

## Material and methods

### Patient population

The present study was approved by the Ethical Evaluation Committee of Zhongshan Hospital and designed using a case-control approach. From among 220 candidates comprising blood donors (60 healthy controls), inpatients (80 patients with AECOPD) and outpatients (80 patients with stable COPD) in Zhongshan Hospital, patients with AECOPD, patients with stable COPD and healthy controls matched for age and sex were recruited into the study between October 2011 and March 2012. The inclusion criteria for patients with COPD were as follows: (1) forced expiratory volume in 1 second (FEV<sub>1</sub>) <80% of predicted value adjusted for age, weight and height, and (2) an improvement in FEV<sub>1</sub> following bronchodilator inhalation <12% of baseline FEV<sub>1</sub>. Patients with asthma who had a persistent airflow obstruction were excluded. Stable COPD was defined according to American Thoracic Society/European Respiratory Society consensus criteria as no requirement for increased treatment above maintenance therapy, other than bronchodilators, for 30 days [1]. AECOPD was the reason for hospital admission and was characterized as a worsening of the patient's respiratory symptoms that was beyond normal day-to-day variations and led to a change in medication [4,19]. Healthy controls enrolled were blood donors at Zhongshan Hospital. Subjects with respiratory diseases, or any family history of lung disease, were excluded. PBMCs



**Figure 1 Details of the study design.** Healthy volunteers and patients with stable chronic obstructive pulmonary disease (sCOPD) or acute exacerbation of COPD (AECOPD) at day 1 (D1), day 3 (D3) or day 10 (D10) of hospital admission of hospital were recruited into the present study according to the criteria stated in the text. All clinical information was collected and transferred into the clinical informatics database using the Digital Evaluation Score System. mRNAs of peripheral blood monocytes were harvested, and gene expression profiles were measured by human gene expression array and subjected to bioinformatics analysis. AECOPD-specific biomarkers were selected by integrating gene functional networks and profiles with clinical informatics data.

**Table 1 Clinical phenotypes of healthy controls, patients with stable chronic obstructive pulmonary disease and patients with acute exacerbation of chronic obstructive pulmonary disease<sup>a</sup>**

Groups	Subject no.	Age (yr)	Smoking status	FEV <sub>1</sub> /FVC%	FEV <sub>1</sub> /pred%	Goddard emphysema score
Control	1	56	Nonsmoker	75	85	0
	2	53	Nonsmoker	80	87	0
	3	62	Nonsmoker	77	91	0
	4	68	Nonsmoker	81	83	0
	5	58	Nonsmoker	79	81	0
	6	67	Nonsmoker	76	90	0
Mean ± SE		60.7 ± 2.5		78.0 ± 1.0	86.2 ± 1.6	0.0 ± 0.0
Stable COPD	1	71	Ex-smoker	57	47	10
	2	75	Ex-smoker	46	66	6
	3	61	Ex-smoker	46	47	8
	4	57	Ex-smoker	38	29	12
	5	59	Ex-smoker	67	66	7
	6	53	Ex-smoker	29	36	11
Mean ± SE		62.7 ± 3.5		47.2 ± 5.5	48.5 ± 6.2	9.0 ± 1.0
AECOPD	1	77	Ex-smoker	40	42	10
	2	72	Ex-smoker	36	27	11
	3	65	Ex-smoker	28	33	16
	4	56	Ex-smoker	48	61	6
	5	61	Ex-smoker	69	55	4
	6	67	Ex-smoker	56	60	8
Mean ± SE		66.3 ± 3.1		46.2 ± 6.0	46.3 ± 5.9	9.2 ± 1.7

<sup>a</sup>AECOPD, Acute exacerbation of chronic obstructive pulmonary disease; COPD, Chronic obstructive pulmonary disease; FEV<sub>1</sub>, Forced expiratory volume in 1 second; FVC, Forced vital capacity; pred, Prediction. Data represent information gathered on days 1, 3 and 10 of hospital admission.

were harvested once from healthy controls and patients with stable COPD, as well as from patients with AECOPD, on the admission day and 3 and 10 days after the admission. Informed consent was given by the subjects themselves before they underwent lung function tests, high-resolution computed tomography and blood collection. The time points used in the present study were selected on the basis of our previous study for collecting plasma samples from healthy controls and from patients

with stable COPD or AECOPD. The details of the study design are explained in Figure 1.

#### Digital evaluation score system

The Digital Evaluation Score System (DESS) is a score index used to translate clinical descriptions and information into clinical informatics, as described previously [20]. Using this instrument, we took into account patient symptoms and signs, biochemical analyses and clinical imaging for patients with stable COPD or AECOPD. Briefly, for the assessment of severity, each component was assigned a score of 0, 1, 2 or 4. The score of 4 as the maximum value indicates far above normal range or much severer condition, and 0 as the minimum value indicates within normal physiological range. After compiling patient data, we added the points for each variable. The DESS scores ranged from 0 to 256 points, with a higher score indicating a severer condition. Patients were scored on the day when their blood samples were collected.


**Table 2 Digital evaluation score system scores<sup>a</sup>**

Patient no.	DESS scores				
	Control	Stable COPD	AE-1	AE-3	AE-10
1	0	30	100	78	43
2	4	27	81	66	46
3	8	35	86	76	36
4	4	55	70	51	30
5	3	38	80	71	35
6	0	47	97	81	30
Mean ± SE	3.2 ± 1.2	38.7 ± 4.3	85.7 ± 4.6	70.5 ± 4.5	36.7 ± 2.7

<sup>a</sup>AE-1, Day 1 of hospital admission; AE-3, Day 3 of hospital admission; AE-10, Day 10 of hospital admission; COPD, Chronic obstructive pulmonary disease; DESS, Digital evaluation score system.

#### Isolation of PBMC RNA

PBMCs were isolated by using BD Vacutainer CPT cell preparation tubes (Becton Dickinson, Franklin Lakes,



**Figure 2 Scatterplots showing variations in gene expression profiles.** Scatterplots of peripheral blood monocytes between patients with stable chronic obstructive pulmonary disease (Stable COPD) (A), acute exacerbation of chronic obstructive pulmonary disease at day 1 of hospital admission (AECOPD-D1) (B), AECOPD at day 3 of hospital admission (AECOPD-D3) (C) or AECOPD at day 10 of hospital admission (AECOPD-D10) (D) compared with healthy controls. Scatterplots also illustrate variations between AECOPD-D1 (E), AECOPD-D3 (F) or AECOPD-D10 (G) and stable COPD; between AECOPD-D3 (H) or AECOPD-D10 (I) with AECOPD-D1; and between AECOPD-D3 and AECOPD-D10 (J).

NJ, USA) according to the manufacturer’s instructions. Approximately 4 ml of whole blood was collected from each subject. Following centrifugation, cells were lysed for RNA isolation. DNase-free total RNA preparation was performed using TRIzol reagent (Life Technologies, Carlsbad, CA, USA) and the RNeasy kit (QIAGEN, Valencia, CA, USA) according to the manufacturers’

recommendations. RNA concentrations were determined by using a NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, USA). RNA quality was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), and samples with an RNA integrity number >6.0 were used.

**Table 3 Genes upregulated in peripheral blood mononuclear cells<sup>a</sup>**

Comparisons	Fold changes in upregulated genes (n)								
	>2	>5	>8	>10	>15	>20	>30	>50	>100
Stable vs Con	4,508	671	217	145	49	27	9	1	0
AE-1 vs Con	3,899	734	334	221	136	86	40	18	3
AE-3 vs Con	4,167	742	358	259	149	97	51	17	5
AE-10 vs Con	3,488	677	331	238	116	74	35	10	1
AE-1 vs Stable	4,067	389	135	80	36	21	9	3	1
AE-3 vs Stable	5,063	620	221	146	56	24	10	1	0
AE-10 vs Stable	5,451	534	178	117	56	33	14	1	0
AE-3 vs AE-1	586	8	2	2	0	0	0	0	0
AE-10 vs AE-1	1,735	164	55	26	10	4	1	0	0
AE-10 vs AE-3	1,706	156	49	29	2	2	1	0	0

<sup>a</sup>Data are number of upregulated genes expressed in peripheral blood mononuclear cells of healthy controls (Con) or of patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on hospital admission day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10).

**Microarray analysis**

The Human 12×135K Gene Expression Array (Roche NimbleGen Systems, Madison, WI, USA), with about 45,000+ human genes and transcripts represented with public domain annotations, was applied for this study. Sample labeling and array hybridization were performed according to the one-color microarray-based gene expression analysis protocol (Roche NimbleGen Systems). Double-stranded cDNA (ds-cDNA) was synthesized from 5 µg of total RNA using an Invitrogen SuperScript reverse transcriptase ds-cDNA synthesis kit (Life Technologies) in the presence of 100 pmol oligo(dT) primers. ds-cDNA was cleaned and labeled in accordance with the NimbleGen gene expression analysis protocol. Briefly, ds-cDNA was incubated with 4 µg of RNase A at 37°C for 10 minutes and cleaned using phenol:chloroform:isoamyl alcohol, followed by ice-cold absolute ethanol precipitation. The purified cDNA was quantified using the NanoDrop ND-1000 spectrophotometer. For Cy3 labeling of cDNA, the NimbleGen one-color DNA labeling kit was used according to the manufacturer’s

**Table 4 Genes upregulated >30-fold in peripheral blood mononuclear cells<sup>a</sup>**

Stable vs control		AE-1 vs control		AE-3 vs control		AE-10 vs control	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
31.7	<i>REXO1L2P</i>	30.3	<i>HP</i>	30.1	<i>FOS</i>	30.8	<i>EMP2</i>
33.0	<i>DEFA1</i>	30.5	<i>LOC152573</i>	30.6	<i>BPIL1</i>	31.0	<i>SEPP1</i>
33.3	<i>DUB3</i>	31.2	<i>INHBA</i>	31.0	<i>ARG1</i>	31.0	<i>FOLR1</i>
37.2	<i>LOC402207</i>	31.4	<i>COL6A3</i>	31.6	<i>N/A</i>	31.1	<i>GPX3</i>
37.3	<i>DUB3</i>	32.4	<i>MPO</i>	31.9	<i>LOC152573</i>	31.2	<i>SFTPB</i>
40.5	<i>LOC402110</i>	32.6	<i>ELF3</i>	32.5	<i>COL6A3</i>	31.4	<i>S100A14</i>
43.1	<i>LOC653600</i>	34.4	<i>CLDN4</i>	32.9	<i>TIMP3</i>	33.1	<i>FOLR1</i>
43.5	<i>N/A</i>	34.9	<i>DCN</i>	33.5	<i>FOS</i>	33.4	<i>CDH5</i>
50.7	<i>MGC45438</i>	35.7	<i>CTGF</i>	34.4	<i>KRT19</i>	34.9	<i>CAV1</i>
		35.7	<i>MMP2</i>	34.7	<i>INHBA</i>	35.4	<i>DLC1</i>
		36.2	<i>MFAP4</i>	35.2	<i>HP</i>	35.6	<i>FOSB</i>
		37.1	<i>EPB42</i>	35.6	<i>CD177</i>	36.1	<i>KRT19</i>
		37.2	<i>H19</i>	36.5	<i>LCN2</i>	36.4	<i>SUSD2</i>
		37.3	<i>ATP1B1</i>	36.9	<i>CTGF</i>	36.9	<i>FN1</i>
		37.5	<i>INHBA</i>	37.9	<i>MMP8</i>	37.2	<i>ADH1C</i>
		38.0	<i>AZU1</i>	38.3	<i>ORM1</i>	37.2	<i>RNASE1</i>
		38.5	<i>LCN2</i>	38.8	<i>ELF3</i>	37.3	<i>IL1RL1</i>
		39.6	<i>CEACAM8</i>	38.9	<i>DCN</i>	41.1	<i>FOLR1</i>
		40.3	<i>CALCA</i>	39.0	<i>CTSG</i>	41.3	<i>DHCR24</i>
		41.4	<i>LOC387763</i>	39.1	<i>CLDN4</i>	41.3	<i>LOC387763</i>
		42.2	<i>CEACAM3</i>	39.3	<i>CALCA</i>	42.0	<i>ADH1B</i>
		45.9	<i>UNQ473</i>	40.0	<i>DCN</i>	43.6	<i>LAMA3</i>
		54.0	<i>BPIL1</i>	40.1	<i>FOSB</i>	45.0	<i>GPX3</i>
		56.2	<i>FN1</i>	41.1	<i>ATP1B1</i>	47.9	<i>DCN</i>
		56.7	<i>CEACAM5</i>	41.6	<i>MFAP4</i>	49.1	<i>EPAS1</i>
		58.4	<i>MMP8</i>	41.8	<i>FN1</i>	50.9	<i>CNN3</i>
		65.0	<i>CALCA</i>	42.0	<i>MMP2</i>	51.5	<i>DCN</i>
		66.3	<i>BPI</i>	42.0	<i>GPR97</i>	54.5	<i>LOC653509</i>
		68.7	<i>DEFA1</i>	42.2	<i>INHBA</i>	56.2	<i>CXCL2</i>
		72.3	<i>COL1A2</i>	45.5	<i>AZU1</i>	58.2	<i>MGC45438</i>
		77.2	<i>CA1</i>	46.0	<i>BPI</i>	58.5	<i>CYP4B1</i>
		80.2	<i>PLUNC</i>	46.4	<i>LOC387763</i>	59.3	<i>CTGF</i>
		83.0	<i>CEACAM1</i>	46.6	<i>MPO</i>	75.8	<i>GPRC5A</i>
		83.9	<i>DEFA4</i>	50.0	<i>HP</i>	88.9	<i>TIMP3</i>
		85.0	<i>COL3A1</i>	50.7	<i>ORM2</i>	149.5	<i>MFAP4</i>
		96.1	<i>DEFA1</i>	53.1	<i>UNQ473</i>		
		99.4	<i>CEACAM5</i>	57.8	<i>AQP9</i>		
		101.2	<i>CEACAM1</i>	59.6	<i>CEACAM5</i>		
		115.8	<i>LOC653600</i>	59.6	<i>BPIL1</i>		
		140.3	<i>DEFA4</i>	61.0	<i>CEACAM1</i>		
				62.8	<i>DEFA1</i>		
				66.5	<i>CEACAM1</i>		
				72.6	<i>DEFA4</i>		

**Table 4 Genes upregulated >30-fold in peripheral blood mononuclear cells<sup>a</sup> (Continued)**

82.5	<i>PLUNC</i>
86.7	<i>DEFA1</i>
92.9	<i>COL1A2</i>
100.8	<i>CEACAM5</i>
101.1	<i>CALCA</i>
109.4	<i>LOC653600</i>
111.5	<i>COL3A1</i>
165.7	<i>DEFA4</i>

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to healthy controls.

guidelines as detailed in its gene expression analysis protocol. One microgram of ds-cDNA was incubated for 10 minutes at 98°C with 1 optical density of Cy3-9mer primer. Next, 100 pmol of deoxynucleoside triphosphates and 100 U of the Klenow fragment (New England Biolabs, Ipswich, MA, USA) were added, and the mix was incubated at 37°C for 2 hours. The reaction was stopped by adding 0.1 vol of 0.5 M ethylenediaminetetraacetic acid, and the labeled ds-cDNA was purified by isopropanol/ethanol precipitation. Microarrays were hybridized at 42°C for 16 to 20 hours with 4 µg of Cy3-labeled ds-cDNA in NimbleGen hybridization buffer/hybridization component A in a hybridization chamber. Following hybridization, washing was performed using the NimbleGen wash buffer kit. After being washed in an ozone-free environment, the slides were scanned using an Axon GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA).

#### Data analysis

For clinical data, all values were expressed as mean ± SE. Analyses were performed using SPSS software (SPSS 18.0; SPSS, Chicago, IL, USA). For microarray analysis, slides were scanned at 5 µm/pixel resolution using the Axon GenePix 4000B microarray scanner piloted by GenePix Pro 6.0 software (Molecular Devices). Scanned images (in TIFF file format) were then imported into NimbleScan software (version 2.5) files for grid alignment and expression data analysis. Expression data were normalized through quantile normalization and the Robust Multi-array Average (RMA) algorithm included in the NimbleScan software. The probe-level (\*\_norm\_RMA.pair) files and gene-level (\*\_RMA.calls) files were generated after normalization. All gene-level files were imported into GeneSpring GX software (version 11.5.1; Agilent Technologies) for further analysis. Differentially expressed genes between two samples were identified by fold change filtering. Hierarchical clustering was performed using the GeneSpring GX software. Gene Ontology (GO) database analysis and pathway

analysis were performed using the standard enrichment computation method. The GO database covers three domains: biological process, cellular component and molecular function. Fisher's exact test was used to find more overlaps between the descriptive list and the GO annotation list than would be expected by chance. The *P*-value denoted the significance of GO term enrichment in the descriptive genes. The gene expression data are publicly available in the Gene Expression Omnibus database [GEO:GSE60399] [21].

## Results

### Clinical informatics analysis

Clinical phenotypes are described in Table 1, including age, sex, smoking status, lung function test results and emphysema scores of the subjects. Control subjects were nonsmokers, and patients with stable COPD or AECOPD were ex-smokers. Because of the severity of disease, lung function tests were not performed at the onset of AECOPD; however, the baseline FEV<sub>1</sub>/forced vital capacity (FVC%) and FEV<sub>1</sub>/predicted percentage of patients with AECOPD were similar to those of patients with stable COPD. In addition, there was no significant difference in the extent of emphysema between patients with stable COPD and those with AECOPD (*P* = 0.47). DESS scores of subjects from each group are shown in Additional file 1. DESS values of patients with stable COPD or AECOPD were significantly higher than those of control subjects (*P* < 0.01), as shown in Table 2. DESS scores represented the severity of COPD and declined as the patient's condition improved. DESS values of patients with AECOPD on day 1 of hospital admission (AE-1) were significantly higher than those on day 3 (AE-3) and day 10 (AE-10) (*P* < 0.05 and *P* < 0.01, respectively) (Table 2).

### Gene expression profiles

The quality of the genetic data obtained after filtering and the distribution of data sets were assessed and visualized by creating box plots, which showed that there were no

**Table 5 Genes upregulated between 20- and 30-fold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared with healthy control subjects<sup>a</sup>**

Stable vs control		AE-1 vs control		AE-3 vs control		AE-10 vs control	
Fold changes	Genes	Fold changes	Gene	Fold changes	Genes	Fold changes	Genes
20.1	<i>P8</i>	20.3	<i>PLAU</i>	20.0	<i>ALPL</i>	20.3	<i>SCNN1A</i>
20.1	<i>REXO1L5P</i>	21.0	<i>COL6A3</i>	20.1	<i>MUC1</i>	20.4	<i>MGC45438</i>
20.2	<i>UNQ473</i>	21.1	<i>SLC25A37</i>	20.2	<i>SPDEF</i>	20.7	<i>FBLN1</i>
20.2	<i>DEFA1</i>	21.1	<i>HIG2</i>	20.3	<i>HIG2</i>	20.7	<i>CLDN4</i>
20.5	<i>LOC440015</i>	21.2	<i>GPRC5A</i>	20.4	<i>KLK11</i>	20.9	<i>SFTPA2</i>
21.1	<i>LOC391749</i>	21.2	<i>CFB</i>	20.4	<i>MGP</i>	21.0	<i>FKBP9</i>
21.3	<i>MGC45438</i>	21.3	<i>LTF</i>	20.4	<i>GPR109A</i>	21.1	<i>FAM107A</i>
21.7	<i>RP11-146D12.2</i>	21.4	<i>VSIG4</i>	21.0	<i>LOC653342</i>	21.3	<i>N/A</i>
22.0	<i>LOC399839</i>	21.7	<i>FOSB</i>	21.1	<i>CFB</i>	21.4	<i>C10orf10</i>
22.9	<i>SPDEF</i>	21.9	<i>SLC25A37</i>	21.3	<i>P8</i>	21.5	<i>SELENBP1</i>
23.0	<i>CLDN4</i>	22.0	<i>ARG1</i>	21.8	<i>PBEF1</i>	21.6	<i>ANXA3</i>
24.7	<i>LOC349196</i>	22.0	<i>SPDEF</i>	21.9	<i>S100P</i>	21.6	<i>IFI27</i>
25.3	<i>STAC2</i>	22.2	<i>LTF</i>	21.9	<i>MS4A3</i>	21.8	<i>C1QC</i>
25.8	<i>REXO1L3P</i>	22.3	<i>FOS</i>	22.4	<i>COL6A3</i>	21.9	<i>SEPP1</i>
26.3	<i>SCGB3A1</i>	22.6	<i>FAM46C</i>	23.1	<i>MANSC1</i>	22.0	<i>KLK11</i>
26.9	<i>RNASE1</i>	22.6	<i>ISLR</i>	23.2	<i>COL1A2</i>	22.1	<i>P8</i>
27.0	<i>AZGP1</i>	22.6	<i>COL1A2</i>	23.2	<i>GCA</i>	22.1	<i>LOC653723</i>
29.5	<i>H19</i>	22.8	<i>ATP1B1</i>	23.3	<i>LTBP2</i>	22.5	<i>LOC391359</i>
		23.8	<i>SCNN1A</i>	23.9	<i>CHI3L1</i>	22.7	<i>LAMB2</i>
		23.8	<i>SERPINE1</i>	24.0	<i>TMC5</i>	22.8	<i>AQP1</i>
		23.8	<i>EPB42</i>	24.2	<i>CD24</i>	24.0	<i>C9orf61</i>
		23.8	<i>C1QC</i>	24.2	<i>HP</i>	24.1	<i>C4BPA</i>
		23.9	<i>RGS1</i>	24.3	<i>ISLR</i>	24.2	<i>LTBP2</i>
		23.9	<i>ORM2</i>	24.3	<i>SIX1</i>	24.3	<i>UNQ473</i>
		24.1	<i>COL5A1</i>	24.5	<i>APOE</i>	24.5	<i>TMEM139</i>
		24.5	<i>MS4A3</i>	24.6	<i>COL3A1</i>	24.6	<i>N/A</i>
		25.6	<i>CD177</i>	24.6	<i>LOC646309</i>	25.7	<i>OLFML3</i>
		25.6	<i>APOE</i>	24.7	<i>CEACAM3</i>	25.9	<i>SNF1LK</i>
		26.4	<i>C20orf114</i>	24.9	<i>AATK</i>	25.9	<i>A2M</i>
		26.6	<i>BPIL1</i>	25.3	<i>LTF</i>	26.4	<i>FXD3</i>
		27.1	<i>CTSG</i>	25.4	<i>ALPL</i>	27.0	<i>HP</i>
		27.4	<i>FOS</i>	25.6	<i>ACSL1</i>	27.1	<i>N/A</i>
		27.6	<i>ALAS2</i>	26.2	<i>CEACAM6</i>	27.4	<i>LOC653509</i>
		28.0	<i>INHBA</i>	26.3	<i>COL5A1</i>	28.0	<i>LDB2</i>
		28.0	<i>TIMP3</i>	26.4	<i>KLK11</i>	28.0	<i>OLFML3</i>
		28.1	<i>COL3A1</i>	26.7	<i>PRTN3</i>	28.5	<i>SFTPA1</i>
		28.1	<i>SLC4A1</i>	26.9	<i>RGS1</i>	28.6	<i>MUC1</i>
		28.2	<i>KLK11</i>	27.3	<i>KCNJ15</i>	29.6	<i>HSPA12B</i>
		28.2	<i>LOC653492</i>	27.4	<i>CAMP</i>	29.8	<i>MFAP4</i>
		28.5	<i>LOC203510</i>	27.6	<i>PLAU</i>		

**Table 5 Genes upregulated between 20- and 30-fold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared with healthy control subjects<sup>a</sup> (Continued)**

28.7	<i>CEACAM3</i>	27.8	<i>LTF</i>
28.8	<i>DCN</i>	27.9	<i>ANXA3</i>
28.9	<i>CEACAM1</i>	28.0	<i>H19</i>
29.0	<i>CEACAM6</i>	28.0	<i>SERPINE1</i>
29.3	<i>SELENBP1</i>	28.1	<i>LTF</i>
29.7	<i>KRT19</i>	28.3	<i>INHBA</i>

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to healthy controls.

significant differences in the distributions of  $\log_2$  ratios among the groups (see Additional file 2: Figure S1). The variation or reproducibility of gene expression between arrays of different groups was visualized and assessed by creating scatterplots, which are shown in Figure 2. There was a significant variation in gene arrays between healthy controls and patients with stable COPD or AECOPD (Figures 2A to 2D) and between patients with stable COPD and AECOPD (Figures 2E to 2G). The variation in gene array data at AE-1 and AE-3 was significantly different from that at AE-10 (Figures 2I and 2J), whereas there was no difference between AE-1 and AE-3 (Figure 2H). The results of hierarchical clustering showed gene expression profiles similar to those revealed by the scatterplots shown in Figure S2 of Additional file 2.

To identify differentially expressed genes, a fold change filtering between each group pair was performed with a threshold fold change  $\geq 2.0$ . There were ten comparison pairs with information for fold changes and regulation (that is, SEQ-ID, log fold change, log or absolute fold change, or regulation), normalized intensities or annotations (that is, GENE\_NAME, synonyms, description, NCBI\_GENE\_ID, chromosome, GO, UniGene ID, The Institute of Genomic Research Database-TDB (TIGRID) or Ensembl ID), as shown in Additional file 3. Table 3 shows the number of genes overexpressed more than twofold, (for example, 4,508, 3,899, 4,167 and 3,488 genes of stable, AE-1, AE-3 and AE-10, respectively, above controls; 4,067, 5,063 or 5,451 genes of AE-1, AE-3 and AE-10, respectively, above stable COPD; 586 genes of AE-3 above AE-1; and 1,735 and 1,706 genes of AE-10, respectively, above AE-1 and AE-3). Tables 4, 5 and 6, respectively, list the genes overexpressed (above controls) in PBMCs from patients with stable COPD, AE-1, AE-3 or AE-10 by more than 30-fold (Table 4), between 20- and 30-fold (Table 5) and between 15- and 20-fold (Table 6). Tables 7, 8 and 9 list the genes overexpressed (above patients with stable COPD) in PBMCs from patients with AE-1, AE-3 or AE-10 by more than 30-fold (Table 7), between 20- and 30-fold (Table 8)

and between 15- and 20-fold. Table 10 presents up-regulated genes in PBMCs of patients at AE-1, AE-3 or AE-10.

Table 11 lists the number of genes downregulated more than twofold, including 4,516, 2,975, 3,426 and 2,798 genes of PBMCs from patients with stable COPD on AE-1, AE-3 and AE-10, respectively, below controls; 3,207, 4,510 and 5288 genes on AE-1, AE-3 and AE-10, respectively, below stable COPD; 598 genes from AE-3 below AE-1; and 2,162 and 1,918 genes from AE-10 below those from AE-1 and AE-3, respectively. Downregulated genes of PBMCs from patients with stable COPD, AE-1, AE-3 or AE-10 greater than tenfold, between 10- and 8-fold or between 8- and 6-fold below healthy control subjects are listed in Tables 12, 13 and 14, respectively. Downregulated genes of PBMCs from patients at AE-1, AE-3 or AE-10 compared to stable COPD, or among patients with AECOPD, are shown in Tables 15 and 16.

#### COPD-specific genes

To search for COPD-specific genes, co-differentially expressed genes of PBMCs from patients with stable COPD or AECOPD were compared with those from control subjects (listed in Additional file 4). There were five groups and four comparison pairs with information regarding fold changes and regulation (that is, SEQ-ID, fold change, log or absolute fold change, or regulation), normalized intensities or annotations (that is, GENE\_NAME, synonyms, description, NCBI\_GENE\_ID, chromosome, GO, UniGene ID, TIGRID or Ensembl ID). Seventy-nine genes were upregulated and 23 genes downregulated in PBMCs from patients with COPD, including both stable COPD and AECOPD, as compared to the healthy control subjects, as shown in Table 17. Of them, 14 genes were upregulated and 2 were downregulated more than tenfold, as compared to control subjects, including carcinoembryonic antigen-related cell adhesion molecule 1, collagen type VI $\alpha$ 3(VI), collagen type I( $\alpha$ )2(I), nucleolar protein 3 (apoptosis repressor with CARD domain), melanophilin, cell surface-associated mucin 1, nuclear



**Table 6 Genes upregulated between 15- and 20-fold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared with healthy control subjects<sup>a</sup>**

Stable vs control		AE-1 vs control		AE-3 vs control		AE-10 vs control	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
15.2	<i>LOC645558</i>	15.0	<i>CNN3</i>	15.0	<i>GPR109B</i>	15.0	<i>USP54</i>
15.7	<i>N/A</i>	15.0	<i>GPT2</i>	15.0	<i>LOC653492</i>	15.0	<i>MGC45438</i>
15.9	<i>LOC653455</i>	15.1	<i>ORM1</i>	15.2	<i>RNASE1</i>	15.2	<i>SLCO2A1</i>
15.9	<i>DUX4</i>	15.1	<i>LOC402110</i>	15.3	<i>FN1</i>	15.3	<i>AGER</i>
16.1	<i>LOC653768</i>	15.1	<i>MDK</i>	15.5	<i>ACSL1</i>	15.3	<i>FLJ11259</i>
16.5	<i>RAB17</i>	15.2	<i>ELF3</i>	15.5	<i>CDH5</i>	15.5	<i>CLEC3B</i>
16.6	<i>LOC653541</i>	15.2	<i>PSG8</i>	15.6	<i>FOLR3</i>	15.8	<i>ADCY4</i>
16.6	<i>LOC391763</i>	15.3	<i>SLC25A37</i>	15.8	<i>PVRL2</i>	16.0	<i>FN1</i>
16.7	<i>LOC642286</i>	15.4	<i>FKBP9</i>	15.9	<i>KRT19</i>	16.1	<i>HP</i>
16.7	<i>S100A14</i>	15.5	<i>C1QB</i>	15.9	<i>MDK</i>	16.1	<i>CKB</i>
16.7	<i>NBPF9</i>	15.6	<i>BPGM</i>	16.0	<i>APOC1</i>	16.1	<i>CYP4B1</i>
16.9	<i>PSG8</i>	15.7	<i>AQP9</i>	16.3	<i>NOL3</i>	16.2	<i>RARRES2</i>
17.0	<i>REXO1L6P</i>	15.7	<i>LOC402207</i>	16.3	<i>ATP1B1</i>	16.3	<i>TSPAN1</i>
17.0	<i>MLPH</i>	15.7	<i>PSG11</i>	16.4	<i>TMC4</i>	16.6	<i>SDC4</i>
17.1	<i>FAM90A7</i>	16.0	<i>KLK11</i>	16.4	<i>VEGF</i>	16.7	<i>ERG</i>
17.4	<i>LOC401650</i>	16.2	<i>KIAA0703</i>	16.6	<i>SPAG4</i>	16.8	<i>LOC653107</i>
17.8	<i>DUB3</i>	16.2	<i>IGFBP5</i>	16.8	<i>LIF</i>	17.2	<i>RAB25</i>
17.9	<i>MGC45438</i>	16.2	<i>IGFBP3</i>	16.8	<i>CCDC80</i>	17.2	<i>COL1A2</i>
18.9	<i>COL3A1</i>	16.2	<i>N/A</i>	16.9	<i>CEACAM3</i>	17.3	<i>DCN</i>
19.1	<i>LOC645732</i>	16.2	<i>SLC25A37</i>	16.9	<i>IGFBP3</i>	17.5	<i>TSPAN13</i>
19.8	<i>LOC392188</i>	16.3	<i>SIX1</i>	17.1	<i>CXCL2</i>	17.6	<i>HSD17B6</i>
20.0	<i>MUC1</i>	16.3	<i>LOC645009</i>	17.2	<i>FKBP9</i>	17.8	<i>RHOB</i>
		16.4	<i>C1QA</i>	17.2	<i>CEACAM1</i>	17.9	<i>KRT19</i>
		16.5	<i>UBD</i>	17.7	<i>ELF3</i>	18.0	<i>AQP9</i>
		16.6	<i>LOC653342</i>	17.7	<i>CNN3</i>	18.2	<i>FOLR1</i>
		17.0	<i>GPR97</i>	17.8	<i>PGLYRP1</i>	18.2	<i>IL1RL1</i>
		17.1	<i>COL1A1</i>	17.9	<i>KRT23</i>	18.2	<i>SERPING1</i>
		17.3	<i>ALPL</i>	18.1	<i>SLC44A4</i>	18.3	<i>MGC35295</i>
		17.4	<i>FBLN1</i>	18.1	<i>SCNN1A</i>	18.4	<i>FLJ43663</i>
		17.5	<i>HIG2</i>	18.4	<i>FBLN1</i>	18.6	<i>TGM2</i>
		17.7	<i>COL8A1</i>	18.5	<i>HPR</i>	18.6	<i>ADH1C</i>
		17.9	<i>TMC5</i>	18.6	<i>SYT7</i>	18.7	<i>KIAA1026</i>
		18.1	<i>LTBP2</i>	18.6	<i>CEACAM8</i>	19.1	<i>DKFZP686A01247</i>
		18.4	<i>SLC25A37</i>	18.8	<i>C1R</i>	19.2	<i>CCDC48</i>
		18.7	<i>CEACAM3</i>	18.8	<i>COL1A1</i>	19.2	<i>ANKRD25</i>
		18.9	<i>MPO</i>	18.9	<i>COL8A1</i>	19.3	<i>DMBT1</i>
		19.0	<i>CD24</i>	18.9	<i>C1QC</i>	19.4	<i>MALL</i>
		19.0	<i>CHI3L1</i>	18.9	<i>SFRP2</i>	19.5	<i>ANXA8</i>
		19.0	<i>DCN</i>	19.0	<i>HIG2</i>	19.5	<i>SPRY4</i>
		19.1	<i>P8</i>	19.2	<i>C1QB</i>	19.7	<i>ELF3</i>
		19.1	<i>CEACAM6</i>	19.2	<i>GPRC5A</i>	19.9	<i>EHD2</i>
		19.1	<i>ACSL1</i>	19.3	<i>MMP25</i>	20.0	<i>DCN</i>

**Table 6 Genes upregulated between 15- and 20-fold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared with healthy control subjects<sup>a</sup> (Continued)**

19.5	<i>PRTN3</i>	19.3	<i>UBD</i>
19.5	<i>LIF</i>	19.3	<i>GADD45A</i>
19.6	<i>LTF</i>	19.4	<i>ISLR</i>
19.7	<i>ANXA3</i>	19.5	<i>ORM1</i>
19.7	<i>C1R</i>	19.5	<i>C20orf114</i>
19.7	<i>MUC1</i>	19.5	<i>LOC203510</i>
19.8	<i>PSG4</i>	19.6	<i>DCN</i>
19.9	<i>HP</i>	19.7	<i>FN1</i>
		19.8	<i>DAAM2</i>
		19.9	<i>FOLR3</i>

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to healthy controls.

protein 1, chemokine (C-X-C motif) ligand 17, claudin 4, ribonuclease 1, imprinted maternally expressed transcript, defensin α1, transcription factor CP2-like 1 and sterol carrier protein 2 (*SCP2*).

**AECOPD-specific genes**

To search for AECOPD-specific genes, co-differentially expressed genes of PBMCs from patients with AECOPD on days 1, 3 and 10 were compared to those from either patients with stable COPD or healthy control subjects (listed in Additional file 4). There were five groups and

**Table 7 Genes upregulated >30-fold in peripheral blood mononuclear cells of patients with AECOPD compared to patients with stable COPD<sup>a</sup>**

AE-1 vs stable		AE-3 vs stable		AE-10 vs stable	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
37.3	<i>MMP8</i>	33.2	<i>LOC646309</i>	30.0	<i>CCDC48</i>
37.6	<i>CEACAM5</i>	34.7	<i>SERPINE1</i>	31.9	<i>LOC653509</i>
38.6	<i>PLUNC</i>	34.9	<i>FOS</i>	32.0	<i>EPAS1</i>
39.4	<i>BPIL1</i>	37.6	<i>CYR61</i>	32.2	<i>CDH5</i>
40.3	<i>CYR61</i>	39.5	<i>CEACAM5</i>	34.4	<i>CLDN5</i>
45.4	<i>CEACAM5</i>	39.6	<i>PLUNC</i>	36.3	<i>SEPP1</i>
55.2	<i>CALCA</i>	40.1	<i>ARG1</i>	38.7	<i>CAV1</i>
56.0	<i>VSIG4</i>	43.5	<i>BPIL1</i>	39.2	<i>CYR61</i>
103.9	<i>CA1</i>	46.0	<i>CEACAM5</i>	42.1	<i>ADH1B</i>
		85.9	<i>CALCA</i>	44.2	<i>CTGF</i>
				44.9	<i>CAV1</i>
				45.1	<i>GPRC5A</i>
				49.8	<i>SEPP1</i>
				81.4	<i>GPX3</i>

<sup>a</sup>Data are from patients with patients with acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to patients with stable chronic obstructive pulmonary disease (Stable).

six comparison pairs with information regarding fold changes and regulation (that is, SEQ-ID, fold change, log or absolute fold change, or regulation), normalized intensities or annotations (that is, GENE\_NAME, synonyms, description, NCBI\_GENE\_ID, chromosome, GO,

**Table 8 Genes upregulated between 20- and 30-fold in peripheral blood mononuclear cells of patients with AECOPD compared to patients with stable COPD<sup>a</sup>**

AE-1 vs stable		AE-3 vs stable		AE-10 vs stable	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
20.1	<i>MS4A3</i>	20.5	<i>GPR97</i>	20.3	<i>TIMP3</i>
21.0	<i>CEACAM6</i>	20.6	<i>ALPL</i>	20.3	<i>SLC6A4</i>
21.1	<i>SLC25A37</i>	20.7	<i>MTHFS</i>	20.4	<i>SFTPA2</i>
21.2	<i>DCN</i>	21.0	<i>FLJ32028</i>	20.6	<i>AKAP2</i>
22.4	<i>SPP1</i>	21.4	<i>ADM</i>	20.7	<i>DST</i>
24.0	<i>TCN1</i>	23.3	<i>ACSL1</i>	21.2	<i>TCF21</i>
24.7	<i>BPIL1</i>	23.3	<i>DCN</i>	21.5	<i>ADH1C</i>
26.4	<i>SLC25A37</i>	24.3	<i>MMP8</i>	21.6	<i>SLIT3</i>
26.6	<i>CTGF</i>	24.5	<i>TCN1</i>	21.7	<i>C9orf61</i>
28.5	<i>ARG1</i>	25.3	<i>FOS</i>	22.5	<i>FOSB</i>
28.6	<i>FOS</i>	25.3	<i>FOSB</i>	25.5	<i>MFAP4</i>
29.5	<i>SERPINE1</i>	27.5	<i>CTGF</i>	26.0	<i>GPX3</i>
		28.3	<i>BPIL1</i>	26.5	<i>DCN</i>
		28.4	<i>VSIG4</i>	26.9	<i>SFTPB</i>
				27.6	<i>FBLN5</i>
				28.1	<i>LOC653509</i>
				28.5	<i>ADH1C</i>
				28.7	<i>SFTPA1</i>
				28.7	<i>TIMP3</i>

<sup>a</sup>Data are from patients with patients with acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to patients with stable chronic obstructive pulmonary disease (Stable).

**Table 9 Genes upregulated between 15- and 20-fold in peripheral blood mononuclear cells of patients with AECOPD compared to patients with stable COPD<sup>a</sup>**

AE-1 vs stable		AE-3 vs stable		AE-10 vs stable	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
15.6	<i>ADM</i>	15.2	<i>LOC387763</i>	15.0	<i>VSIG4</i>
15.8	<i>DEFA4</i>	15.2	<i>MMP25</i>	15.6	<i>IL1RL1</i>
16.2	<i>DEFA4</i>	15.3	<i>USP15</i>	15.8	<i>PZP</i>
16.2	<i>C1R</i>	15.5	<i>C1R</i>	16.0	<i>LDB2</i>
16.9	<i>GPNMB</i>	15.8	<i>KCNJ15</i>	16.2	<i>FLJ43663</i>
17.2	<i>DCN</i>	15.9	<i>GADD45A</i>	16.5	<i>N/A</i>
17.3	<i>FAM46C</i>	15.9	<i>LRRC4</i>	16.6	<i>CD55</i>
17.6	<i>ALAS2</i>	16.3	<i>GLT1D1</i>	16.8	<i>CXCL2</i>
17.6	<i>CALCA</i>	16.4	<i>CD55</i>	16.9	<i>IL1RL1</i>
17.9	<i>GPNMB</i>	16.5	<i>CEACAM6</i>	17.0	<i>RHOB</i>
18.2	<i>DUSP1</i>	16.6	<i>SPP1</i>	17.1	<i>DLC1</i>
18.2	<i>CEACAM6</i>	16.7	<i>SLC25A37</i>	17.2	<i>VIPR1</i>
18.2	<i>SLC25A37</i>	17.1	<i>ORM1</i>	17.2	<i>CRYAB</i>
18.7	<i>FOS</i>	17.2	<i>CALCA</i>	17.8	<i>CNN3</i>
18.9	<i>SLC25A37</i>	17.3	<i>DUSP1</i>	18.1	<i>DCN</i>
		17.5	<i>CD177</i>	18.1	<i>IFI27</i>
		17.6	<i>GPNMB</i>	18.2	<i>SLIT2</i>
		17.7	<i>MS4A3</i>	18.3	<i>RASIP1</i>
		17.8	<i>DCN</i>	18.8	<i>MFAP4</i>
		17.8	<i>GPR109A</i>	19.0	<i>CAMK2N1</i>
		17.9	<i>BASP1</i>	19.0	<i>CD55</i>
		17.9	<i>IL8RB</i>	19.5	<i>AGER</i>
		18.4	<i>AQP9</i>	19.9	<i>DKFZP686A01247</i>
		18.7	<i>DEFA4</i>		
		18.8	<i>QPCT</i>		
		19.0	<i>PBEF1</i>		
		19.0	<i>BASP1</i>		
		19.0	<i>CEACAM6</i>		
		19.2	<i>GNG10</i>		
		19.7	<i>GPNMB</i>		
		19.7	<i>GCA</i>		
		20.0	<i>RNASE3</i>		

<sup>a</sup>Data are from patients with patients with acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to patients with stable chronic obstructive pulmonary disease (Stable).

UniGene ID, TIGRID or Ensembl ID). As compared with both patients with stable COPD and healthy control subjects, 58 genes were upregulated more than fivefold and 238 downregulated more than twofold in patients with AECOPD. Of them, eight upregulated (more than tenfold) and eight downregulated (more than threefold) genes are listed in Table 18. These

**Table 10 Genes upregulated more than fivefold in peripheral blood mononuclear cells of patients with AECOPD<sup>a</sup>**

AE-3 vs AE-1		AE-10 vs AE-1		AE-10 vs AE-3	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
5.1	<i>TMEM50A</i>	10.3	<i>SUSD2</i>	10.1	<i>SLCO2A1</i>
5.2	<i>BCL2A1</i>	10.6	<i>TCF21</i>	10.1	<i>OAS3</i>
5.3	<i>C6orf32</i>	10.6	<i>FOLR1</i>	10.1	<i>C4BPA</i>
6.0	<i>PI3</i>	10.7	<i>C9orf61</i>	10.2	<i>DMBT1</i>
7.0	<i>KCNJ15</i>	10.9	<i>LOC653107</i>	10.4	<i>VSIG2</i>
7.6	<i>CISH</i>	11.3	<i>AGER</i>	10.4	<i>LOC653107</i>
10.4	<i>CISH</i>	12.0	<i>SLIT2</i>	10.5	<i>ITLN2</i>
10.7	<i>CISH</i>	12.7	<i>ITLN2</i>	10.7	<i>CX3CR1</i>
		12.9	<i>FLRT3</i>	10.7	<i>MSLN</i>
		13.1	<i>VIPR1</i>	10.8	<i>SOCS2</i>
		13.2	<i>SOCS2</i>	10.9	<i>LOC653107</i>
		13.3	<i>IL1RL1</i>	11.7	<i>FOLR1</i>
		13.4	<i>LOC653107</i>	11.7	<i>GPX3</i>
		13.8	<i>C4BPA</i>	11.8	<i>CLIC5</i>
		14.4	<i>CYP4B1</i>	11.8	<i>SLIT2</i>
		14.4	<i>LAMA3</i>	11.9	<i>LOC653107</i>
		15.1	<i>CYP4B1</i>	12.1	<i>AQP1</i>
		15.2	<i>ADH1C</i>	12.6	<i>LOC653509</i>
		15.7	<i>MGC35295</i>	12.6	<i>ADH1C</i>
		15.8	<i>GPX3</i>	12.7	<i>ADH1C</i>
		17.0	<i>IL1RL1</i>	12.8	<i>ADH1B</i>
		17.9	<i>MSLN</i>	12.9	<i>LAMA3</i>
		20.0	<i>ADH1C</i>	13.6	<i>IL1RL1</i>
		22.4	<i>ADH1B</i>	13.6	<i>CYP4B1</i>
		24.5	<i>SLC6A4</i>	13.9	<i>FAM107A</i>
		35.3	<i>FOLR1</i>	14.2	<i>LOC653107</i>
				14.9	<i>CYP4B1</i>
				22.0	<i>MGC35295</i>
				31.2	<i>SLC6A4</i>

<sup>a</sup>Data are from day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission.

genes include FBJ murine osteosarcoma viral oncogene homologue (FOS); interferon  $\alpha$ -inducible protein 27 (IFI27); cysteine-rich angiogenic inducer 61 (CYR61), connective tissue growth factor (CTGF); G protein-coupled receptor family C group 5 member A (GPRC5A); FBJ murine osteosarcoma viral oncogene homologue B (FOSB); decorin (DCN); hypothetical LOC387763 (LOC387763); killer cell immunoglobulin-like receptor, two domains, short cytoplasmic tail, 2 (KIR2DS2); SH2 domain containing 1B (SH2D1B); CD8b molecule (CD8B); olfactory receptor family 2, subfamily W, member 5 (OR2W5); fibroblast

**Table 11 Number of downregulated genes in peripheral blood mononuclear cells of healthy control subjects, patients with stable COPD and patients with AECOPD<sup>a</sup>**

Compared pairs	Fold changes in upregulated genes (n)									
	>2	>5	>6	>8	>10	>15	>20	>30	>50	>100
Stable vs Con	4,516	135	55	9	4	2	1	0	0	0
AE-1 vs Con	2,975	182	107	47	22	7	4	1	0	0
AE-3 vs Con	3,426	225	149	65	35	11	5	2	0	0
AE-10 vs Con	2,798	124	73	31	16	2	1	1	0	0
AE-1 vs Stable	3,207	33	16	4	4	2	0	0	0	0
AE-3 vs Stable	4,510	125	71	21	8	3	1	0	0	0
AE-10 vs Stable	5,288	445	236	97	49	20	8	3	0	0
AE-3 vs AE-1	598	32	23	17	5	3	2	0	0	0
AE-10 vs AE-1	2,162	261	168	82	43	21	14	10	5	1
AE-10 vs AE-3	1,918	192	130	66	36	15	9	6	4	0

<sup>a</sup>Data are from controls (Con) or patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission.

growth factor binding protein 2 (*FGF2*); and transcription factor 7 (*TCF7*).

#### Dynamic change in gene expression in patients with AECOPD

Dynamic changes (down–down, down–up, up–down and up–up) of co–differentially expressed genes of PBMCs from patients with AECOPD are listed in Additional file 4, including fold changes and regulation (that is, SEQ-ID, fold change, log or absolute fold change, or regulation), normalized intensities or annotations (that is, GENE\_NAME, synonyms, description, NCBI\_GENE\_ID, chromosome, GO, UniGene ID, TIGRID or Ensembl ID). Table 19 shows the dynamic changes in the patterns of down–down (52 genes), down–up (131 genes), up–down (238 genes) and up–up (8 genes) more than twofold, as compared with the gene expression on the previous day. The major genes of PBMCs from patients with AECOPD were aminolevulinate, delta-, synthase 2 (*ALAS2*), erythrocyte membrane protein band 4.2 (*EPB42*) and carbonic anhydrase I (*CA1*) in a down–down pattern; selenium-binding protein 1 (*SELENBP1*) and myosin heavy chain 9, non-muscle (*MYH9*), in a down–up pattern; HLA complex group 27 (*HCG27*), BCL2-related protein A1 (*BCL2A1*), G protein–coupled receptors 109A and 109B (*GPR109A* and *GPR109B*) in an up–down pattern; and zeta protein kinase C (*PRKCZ*), ATP-binding cassette, subfamily A, member 8 (*ABCA8*), and folate receptor 1 (adult) (*FOLR1*) in an up–up pattern (Table 19). Levels of genes from patients with AECOPD were also compared with those from patients with stable COPD, as shown in Figure 3, where positive or negative values indicate up- or downregulation as compared with those from patients with stable COPD. When correlated with DESS, *ALAS2* and *CA1* had similar patterns of change with DESS.

#### Gene ontology analysis and pathway analysis

Within ten comparison pairs, up- or downregulated genes mainly involved in the biological process are shown in Figures S3 and S4 of Additional file 2, those in cellular components are shown in Figures S5 and S6 of Additional file 2 and those in molecular functions are shown in Figures S7 and S8 of Additional file 2. Additional file 5 lists gene numbers for ten comparison pairs with certain GO terms and different ranges of enrichment scores.

In the biological process, COPD-specific upregulated genes were involved mainly in peptide cross-linking, blood vessel development, biological adhesion or cell adhesion (Figure 4A). COPD-specific downregulated genes were involved mainly in T cell receptor signaling pathways, antigen receptor–mediated signaling pathways, immune response–activating cell surface receptor signaling pathways or steroid biosynthetic process (Figure 4B). AECOPD-specific genes upregulated in response to organic substance, response to wounding, multicellular organismal process or response to chemical stimulus are shown in Figure 4C. AECOPD-specific downregulated genes were involved mainly in the regulation of immune response and the immune system process or in the immune response and immune system process themselves (Figure 4D). In the cellular component, COPD-specific upregulated genes were involved mainly in the extracellular region, the extracellular matrix part, the proteinaceous extracellular matrix or the extracellular matrix (Figure 5A). COPD-specific downregulated genes were involved mainly in the major histocompatibility complex class II (MHC II) protein complex, microbody lumen, peroxisomal matrix or MHC II protein complex (Figure 5B). AECOPD-specific upregulated genes were involved mainly in the extracellular

**Table 12 Genes downregulated more than tenfold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects<sup>a</sup>**

Stable vs Con		AE-1 vs Con		AE-3 vs Con		AE-10 vs Con	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
10.7	<i>EIF3S6</i>	10.3	<i>HAND1</i>	10.2	<i>GZMK</i>	10.0	<i>C21orf7</i>
10.7	<i>YLPM1</i>	10.3	<i>CD8B</i>	10.5	<i>CXCR3</i>	10.0	<i>NELL2</i>
16.1	<i>TFCP2L1</i>	10.4	<i>UBASH3A</i>	10.6	<i>AK5</i>	10.4	<i>C21orf7</i>
21.0	<i>SCP2</i>	10.8	<i>TRA@</i>	10.7	<i>TRA@</i>	10.4	<i>GFI1B</i>
		10.9	<i>TRBV3-1</i>	10.7	<i>IL24</i>	10.5	<i>LOC129293</i>
		11.2	<i>CD8B</i>	10.9	<i>CD6</i>	10.5	<i>LOC123876</i>
		11.4	<i>MAL</i>	10.9	<i>N/A</i>	10.7	<i>HIST1H3H</i>
		11.4	<i>LOC643514</i>	11.2	<i>KIAA0748</i>	11.1	<i>IL24</i>
		11.5	<i>NELL2</i>	11.4	<i>LCK</i>	11.4	<i>GFI1B</i>
		11.7	<i>TTC24</i>	11.5	<i>CD8B</i>	11.9	<i>CRTAC1</i>
		12.7	<i>CD8B</i>	12.3	<i>APBB1</i>	11.9	<i>OR10A4</i>
		13.1	<i>LEF1</i>	12.3	<i>IL12RB1</i>	11.9	<i>SAA3P</i>
		13.8	<i>TCF7</i>	12.5	<i>TTC24</i>	12.7	<i>TTC24</i>
		14.2	<i>LOC129293</i>	12.5	<i>GFI1B</i>	14.9	<i>TFCP2L1</i>
		14.5	<i>LOC129293</i>	12.5	<i>CRTAC1</i>	18.6	<i>SCP2</i>
		15.6	<i>TCF7</i>	12.6	<i>TRBV3-1</i>	32.3	<i>UNQ470</i>
		16.1	<i>TCF7</i>	12.6	<i>ATG9B</i>		
		16.8	<i>CD8B</i>	12.9	<i>ABLIM1</i>		
		21.8	<i>TFCP2L1</i>	12.9	<i>LOC129293</i>		
		25.4	<i>CRTAC1</i>	13.0	<i>CD8B</i>		
		27.9	<i>SCP2</i>	13.1	<i>CD28</i>		
		44.1	<i>UNQ470</i>	13.1	<i>GRAP2</i>		
				14.3	<i>UBASH3A</i>		
				14.4	<i>CCR7</i>		
				15.0	<i>LOC129293</i>		
				16.0	<i>CD8B</i>		
				18.1	<i>UNQ470</i>		
				18.7	<i>SCP2</i>		
				18.8	<i>LEF1</i>		
				19.3	<i>LEF1</i>		
				23.5	<i>CD8B</i>		
				24.3	<i>TCF7</i>		
				25.1	<i>TCF7</i>		
				30.4	<i>TCF7</i>		
				32.0	<i>TFCP2L1</i>		

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to healthy controls (Con).

region part, the extracellular matrix, the extracellular space or the extracellular region (Figure 5C). AECOPD-specific downregulated genes were involved mainly in the cell periphery and the plasma membrane and were integral to the plasma membrane and intrinsic to the plasma membrane (Figure 5D). In molecular function,

COPD-specific upregulated genes participated mainly in extracellular matrix structural constituent, platelet-derived growth factor binding, serine-type endopeptidase activity and protein binding (Figure 6A). COPD-specific downregulated genes were involved mainly in nucleoside kinase activity, MHC class II receptor activity, C-acyltransferase

**Table 13 Genes downregulated between eight- and tenfold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects<sup>a</sup>**

Stable vs Con		AE-1 vs Con		AE-3 vs Con		AE-10 vs Con	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
8.2	<i>AK5</i>	8.1	<i>CD3G</i>	8.0	<i>TRBV19</i>	8.1	<i>HFE2</i>
8.6	<i>TRA@</i>	8.2	<i>LY9</i>	8.0	<i>OTOA</i>	8.2	<i>TRA@</i>
9.1	<i>ZC3HAV1</i>	8.2	<i>AK5</i>	8.1	<i>CD7</i>	8.6	<i>UNQ470</i>
9.3	<i>MAL</i>	8.2	<i>C21orf7</i>	8.1	<i>GRAP2</i>	8.6	<i>CD248</i>
9.7	<i>TMEM50B</i>	8.2	<i>TRBC1</i>	8.1	<i>TNFRSF25</i>	8.6	<i>XG</i>
		8.3	<i>ANKDD1A</i>	8.2	<i>C21orf7</i>	8.7	<i>ATG9B</i>
		8.4	<i>CD6</i>	8.2	<i>EPHA6</i>	8.8	<i>LOC339778</i>
		8.4	<i>RPS6KB1</i>	8.2	<i>GIMAP5</i>	8.9	<i>TCF7</i>
		8.5	<i>TMEM50B</i>	8.3	<i>1-Sep</i>	8.9	<i>CCR7</i>
		8.7	<i>YLPM1</i>	8.3	<i>UBASH3A</i>	9.2	<i>LOC644663</i>
		8.7	<i>TRBV19</i>	8.4	<i>GIMAP7</i>	9.4	<i>LOC129293</i>
		8.8	<i>FLT3LG</i>	8.5	<i>MGC23244</i>	9.5	<i>MGC39606</i>
		8.9	<i>N/A</i>	8.6	<i>LOC645852</i>	9.7	<i>GZMK</i>
		9.1	<i>LEF1</i>	8.7	<i>SCAP1</i>	9.9	<i>AK5</i>
		9.1	<i>GZMK</i>	9.0	<i>HIST1H3H</i>	9.9	<i>TCF7</i>
		9.1	<i>KIAA0748</i>	9.0	<i>HFE2</i>		
		9.2	<i>ABLIM1</i>	9.2	<i>GFI1B</i>		
		9.5	<i>C21orf7</i>	9.2	<i>TMEM50B</i>		
		9.5	<i>ATG9B</i>	9.5	<i>N/A</i>		
		9.6	<i>LCK</i>	9.5	<i>C21orf7</i>		
		9.6	<i>LOC647353</i>	9.6	<i>GATA3</i>		
		9.8	<i>CCR7</i>	9.7	<i>C21orf7</i>		
		9.8	<i>UNQ470</i>	9.7	<i>CD247</i>		
		9.9	<i>OR10A4</i>	9.8	<i>LCK</i>		
		9.9	<i>IL12RB1</i>	9.8	<i>KSP37</i>		
				9.9	<i>FAIM3</i>		
				9.9	<i>SPOCK2</i>		
				9.9	<i>TRA@</i>		
				9.9	<i>SH2D1B</i>		
				10.0	<i>GRAP2</i>		

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to healthy controls (Con).

activity and ephrin receptor activity (Figure 6B). AECOPD-specific upregulated genes were involved mainly in protein binding, growth factor binding, calcium ion binding and polysaccharide binding (Figure 6C). AECOPD-specific downregulated genes were involved mainly in receptor activity, signaling receptor activity, molecular transducer activity and signal transducer activity (Figure 6D).

COPD-specific upregulated genes also participated in extracellular matrix receptor interaction, protein digestion and absorption, focal adhesion and the phosphatidylinositol 3-kinase-Akt signaling pathway (Figure 7A). AECOPD-specific upregulated genes participated in Chagas

disease, complement and coagulation cascades, pertussis and *Staphylococcus aureus* infection (Figure 7B). AECOPD-specific downregulated genes participated in antigen processing and presentation, natural killer cell-mediated cytotoxicity, graft-versus-host disease and thyroid cancer (Figure 7C).

## Discussion

PBMCs play a critical and important role in the occurrence of AECOPD, owing to less capacity for balancing the proinflammatory immune response caused by infection and for secreting adequate amounts of anti-inflammatory

**Table 14 Genes downregulated between six- and eightfold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects<sup>a</sup>**

Stable vs Con		AE-1 vs Con		AE-3 vs Con		AE-10 vs Con	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
6.0	<i>NDUFV3</i>	6.0	<i>MAL</i>	6.0	<i>IL7R</i>	6.0	<i>HKDC1</i>
6.0	<i>C17orf45</i>	6.0	<i>ARHGAP12</i>	6.0	<i>CD28</i>	6.1	<i>TANC2</i>
6.1	<i>MAL</i>	6.0	<i>TRAPPC4</i>	6.0	<i>KIR2DS1</i>	6.1	<i>FAM5B</i>
6.1	<i>CXCR6</i>	6.0	<i>GNLY</i>	6.0	<i>FLJ20647</i>	6.2	<i>KIAA0748</i>
6.1	<i>SUCLA2</i>	6.0	<i>N/A</i>	6.1	<i>N/A</i>	6.3	<i>CD40LG</i>
6.1	<i>C21orf7</i>	6.0	<i>LOC642376</i>	6.1	<i>CLDN1</i>	6.3	<i>PCDH10</i>
6.2	<i>TNPO1</i>	6.0	<i>MYOZ3</i>	6.1	<i>TRBV5-4</i>	6.3	<i>LOC644273</i>
6.2	<i>LOC643514</i>	6.1	<i>FLJ20647</i>	6.1	<i>CARD11</i>	6.3	<i>CD96</i>
6.2	<i>ALS2CR13</i>	6.1	<i>CD96</i>	6.1	<i>LOC441320</i>	6.3	<i>TRA@</i>
6.2	<i>CREB1</i>	6.2	<i>MAL</i>	6.1	<i>ACADSB</i>	6.3	<i>TRBV3-1</i>
6.2	<i>C17orf45</i>	6.2	<i>GIMAP5</i>	6.1	<i>NXPH4</i>	6.4	<i>TRA@</i>
6.3	<i>NELL2</i>	6.2	<i>CLDN1</i>	6.2	<i>SCNN1D</i>	6.4	<i>LOC642483</i>
6.3	<i>C6orf32</i>	6.2	<i>CD3D</i>	6.2	<i>MTMR1</i>	6.5	<i>ANKDD1A</i>
6.3	<i>LOC642455</i>	6.2	<i>LY9</i>	6.2	<i>MAL</i>	6.5	<i>N/A</i>
6.4	<i>GMDS</i>	6.3	<i>LOC123876</i>	6.2	<i>ZAP70</i>	6.5	<i>N/A</i>
6.4	<i>ABHD6</i>	6.3	<i>TNFRSF25</i>	6.3	<i>MAL</i>	6.5	<i>LY9</i>
6.4	<i>DAPP1</i>	6.3	<i>C21orf7</i>	6.3	<i>IL2RB</i>	6.6	<i>CD8B</i>
6.4	<i>SH3BGRL</i>	6.3	<i>LOC645885</i>	6.3	<i>EDG8</i>	6.6	<i>MGC26597</i>
6.5	<i>IL7R</i>	6.3	<i>BLOC1S3</i>	6.3	<i>HKDC1</i>	6.7	<i>TRBV19</i>
6.6	<i>LOC441601</i>	6.3	<i>LOC644727</i>	6.3	<i>SCAP1</i>	6.7	<i>LOC145783</i>
6.6	<i>GPR18</i>	6.4	<i>CCDC45</i>	6.3	<i>LOC440455</i>	6.8	<i>CD8B</i>
6.7	<i>P2RX5</i>	6.4	<i>C21orf7</i>	6.3	<i>CD300E</i>	6.9	<i>C21orf7</i>
6.7	<i>LY9</i>	6.5	<i>CD28</i>	6.4	<i>LY9</i>	6.9	<i>UBASH3A</i>
6.8	<i>GGPS1</i>	6.5	<i>LOC440455</i>	6.4	<i>KIR2DS2</i>	7.0	<i>LOC400768</i>
6.8	<i>EIF3S6</i>	6.5	<i>IL24</i>	6.4	<i>SLAMF6</i>	7.1	<i>CD8B</i>
6.8	<i>ARHGAP15</i>	6.5	<i>GHRL</i>	6.4	<i>SAA3P</i>	7.1	<i>HAND1</i>
6.8	<i>SF3B1</i>	6.5	<i>FAM113B</i>	6.4	<i>SF3A2</i>	7.2	<i>LOC126075</i>
6.8	<i>GPR89A</i>	6.5	<i>LOC644663</i>	6.5	<i>UNQ470</i>	7.2	<i>TNFRSF7</i>
6.9	<i>LOC129293</i>	6.5	<i>C15orf37</i>	6.5	<i>C6orf21</i>	7.3	<i>LEF1</i>
6.9	<i>CPNE3</i>	6.5	<i>MAL</i>	6.6	<i>CD96</i>	7.3	<i>HLA-DOA</i>
6.9	<i>LY9</i>	6.5	<i>LOC644445</i>	6.6	<i>CD244</i>	7.4	<i>LOC646279</i>
7.0	<i>PIP3-E</i>	6.6	<i>LOC126075</i>	6.6	<i>N/A</i>	7.4	<i>YLPM1</i>
7.0	<i>TAF9</i>	6.6	<i>1-Sep</i>	6.6	<i>KLRK1</i>	7.4	<i>LOC643514</i>
7.0	<i>N/A</i>	6.6	<i>UBASH3A</i>	6.6	<i>C16orf5</i>	7.5	<i>MTMR1</i>
7.0	<i>KIAA0748</i>	6.7	<i>SAA3P</i>	6.6	<i>TRBC1</i>	7.6	<i>NOG</i>
7.1	<i>CD55</i>	6.8	<i>CD6</i>	6.6	<i>LOC339778</i>	7.7	<i>TCF7</i>
7.2	<i>EIF3S6</i>	6.8	<i>TRBV5-4</i>	6.7	<i>GNLY</i>	7.7	<i>KIAA0748</i>
7.2	<i>PGRMC2</i>	6.9	<i>1-Sep</i>	6.7	<i>LDLRAP1</i>	7.7	<i>C21orf7</i>
7.3	<i>C21orf7</i>	6.9	<i>LOC129293</i>	6.8	<i>HAND1</i>	7.7	<i>PRDM9</i>
7.4	<i>PSMD6</i>	7.0	<i>SCNN1D</i>	6.8	<i>CD3D</i>	7.7	<i>FCER2</i>
7.5	<i>ABLIM1</i>	7.0	<i>SIT1</i>	6.8	<i>FLJ45825</i>	7.9	<i>CD8B</i>
7.6	<i>STAG2</i>	7.1	<i>GATA3</i>	6.8	<i>SF3A2</i>	8.0	<i>LEF1</i>

**Table 14 Genes downregulated between six- and eightfold in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects<sup>a</sup> (Continued)**

7.8	<i>CCDC45</i>	7.1	<i>CD7</i>	6.8	<i>CXCR3</i>
7.8	<i>UNQ470</i>	7.1	<i>CDKN3</i>	6.8	<i>KIR3DL3</i>
7.9	<i>LY9</i>	7.2	<i>SCAP1</i>	6.8	<i>LAT</i>
8.0	<i>CD40LG</i>	7.3	<i>TRA@</i>	6.9	<i>CD52</i>
		7.3	<i>LY9</i>	6.9	<i>TNFRSF7</i>
		7.3	<i>DDAH1</i>	6.9	<i>LOC442726</i>
		7.3	<i>TRA@</i>	6.9	<i>3-Sep</i>
		7.5	<i>TNFRSF7</i>	6.9	<i>KIAA0748</i>
		7.5	<i>KIAA0748</i>	6.9	<i>XG</i>
		7.6	<i>ITM2A</i>	6.9	<i>KIAA1549</i>
		7.6	<i>CD5</i>	7.0	<i>RNF157</i>
		7.6	<i>D4S234E</i>	7.0	<i>SIT1</i>
		7.6	<i>CD300E</i>	7.0	<i>CD1C</i>
		7.7	<i>APBB1</i>	7.0	<i>SLC16A10</i>
		7.8	<i>CD3D</i>	7.0	<i>CD3G</i>
		7.8	<i>LCK</i>	7.1	<i>CD6</i>
		7.8	<i>UBASH3A</i>	7.1	<i>LY9</i>
		7.9	<i>XG</i>	7.1	<i>FLT3LG</i>
				7.1	<i>LOC647353</i>
				7.2	<i>LOC123876</i>
				7.2	<i>CX3CR1</i>
				7.2	<i>LOC126075</i>
				7.3	<i>NELL2</i>
				7.4	<i>LY9</i>
				7.4	<i>MAL</i>
				7.4	<i>KIR2DS2</i>
				7.4	<i>CHIA</i>
				7.4	<i>BIN1</i>
				7.5	<i>CCDC78</i>
				7.5	<i>MAL</i>
				7.5	<i>C21orf7</i>
				7.5	<i>KIR2DL4</i>
				7.6	<i>CD6</i>
				7.6	<i>CD3D</i>
				7.7	<i>1-Sep</i>
				7.7	<i>LCK</i>
				7.8	<i>ITM2A</i>
				7.8	<i>TRA@</i>
				7.9	<i>SIT1</i>
				7.9	<i>CD5</i>
				8.0	<i>CD8A</i>
				8.0	<i>LOC129293</i>

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) after the hospital admission, as compared to healthy controls (Con).



**Table 15 Genes downregulated more than fivefold in peripheral blood mononuclear cells of patients with AECOPD compared to patients with stable COPD<sup>a</sup>**

AE-1 vs Stable		AE-3 vs Stable		AE-10 vs Stable	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
5.0	<i>PRODH</i>	10.2	<i>KSP37</i>	10.1	<i>LOC646781</i>
5.1	<i>MT1F</i>	10.3	<i>DUB3</i>	10.1	<i>LOC389634</i>
5.1	<i>OR2A7</i>	10.6	<i>DUB3</i>	10.1	<i>LOC441056</i>
5.3	<i>CD8B</i>	10.8	<i>TCF7</i>	10.1	<i>LOC340243</i>
5.4	<i>CGI-38</i>	11.2	<i>CX3CR1</i>	10.2	<i>C1QL2</i>
5.4	<i>DMBT1</i>	17.6	<i>MGC35295</i>	10.2	<i>LOC653541</i>
5.4	<i>N/A</i>	19.9	<i>STAC2</i>	10.2	<i>LOC158318</i>
5.4	<i>GNLY</i>	25.0	<i>AZGP1</i>	10.3	<i>N/A</i>
5.5	<i>LCK</i>			10.4	<i>LOC644373</i>
5.5	<i>DZIP1</i>			10.6	<i>SPDEF</i>
5.6	<i>TCF7</i>			10.7	<i>DUX1</i>
5.6	<i>MGC45438</i>			10.9	<i>LOC643001</i>
5.6	<i>UNQ470</i>			11.1	<i>LOC391767</i>
5.8	<i>MGLL</i>			11.2	<i>LOC645509</i>
5.8	<i>B4GALNT3</i>			11.7	<i>FLJ36131</i>
5.9	<i>CGI-38</i>			11.8	<i>LOC441323</i>
5.9	<i>CGI-38</i>			11.9	<i>LOC440015</i>
6.1	<i>LOC388886</i>			11.9	<i>LOC441812</i>
6.1	<i>GNLY</i>			12.0	<i>TCEB3C</i>
6.2	<i>N/A</i>			12.1	<i>SPDEF</i>
6.4	<i>CD8B</i>			12.3	<i>DUX4</i>
6.4	<i>AEBP2</i>			12.5	<i>LOC285697</i>
6.4	<i>EDG8</i>			12.9	<i>LOC646066</i>
6.5	<i>PRDM16</i>			13.3	<i>LOC441873</i>
6.8	<i>CX3CR1</i>			13.6	<i>LOC645402</i>
7.0	<i>MGC45438</i>			13.7	<i>LOC285563</i>
7.3	<i>MST1</i>			13.9	<i>LOC391763</i>
7.4	<i>LOC644088</i>			14.4	<i>DUB3</i>
7.5	<i>EDG8</i>			14.7	<i>LOC391766</i>
10.1	<i>MGC45438</i>			15.0	<i>LOC392197</i>
12.6	<i>MGC35295</i>			15.0	<i>REXO1L2P</i>
15.5	<i>STAC2</i>			15.2	<i>DUB3</i>
19.1	<i>AZGP1</i>			15.2	<i>LOC402199</i>
				15.7	<i>LOC653442</i>
				15.8	<i>LOC653455</i>
				16.0	<i>LOC402207</i>
				16.5	<i>LOC391745</i>
				16.7	<i>LOC392188</i>
				18.1	<i>REXO1L6P</i>
				19.1	<i>LOC391764</i>
				19.4	<i>DUB3</i>

**Table 15 Genes downregulated more than fivefold in peripheral blood mononuclear cells of patients with AECOPD compared to patients with stable COPD<sup>a</sup>**

(Continued)	
20.6	<i>LOC645836</i>
21.0	<i>LOC391749</i>
23.8	<i>LOC402110</i>
24.2	<i>REXO1L7P</i>
29.6	<i>REXO1L1</i>
30.0	<i>STAC2</i>
33.5	<i>REXO1L3P</i>
39.7	<i>REXO1L5P</i>

<sup>a</sup>Data are from patients acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) after the hospital admission, as compared to patients with stable chronic obstructive pulmonary disease (Stable).

cytokines [22]. The fact that patients with COPD are more susceptible to acute exacerbation has been suggested to be associated with PBMC dysfunction and failure of adaptation to infection, stimuli or hypoxia, although there have been not yet studies on the phenotypes of PBMCs in AECOPD. For example, PBMCs from patients with COPD could not induce hypoxia-inducible factor 1 and vascular endothelial growth factor, owing to a reduction in histone deacetylase 7 under hypoxic condition [23]. It was suggested that overproduction of proinflammatory cytokines (*CXCL6* and interleukin 6 (*IL-6*)) from human PBMCs could be stimulated by the infection through activation of Toll-like receptor 4, nicotinamide adenine dinucleotide phosphate oxidase phosphatidylinositol 3-kinase and nuclear factor  $\kappa$ B [24], at least as partial mechanisms by which PBMCs may be involved in the occurrence of AECOPD. The present study provides initial evidence that dynamic alterations of PBMC genetic phenotypes occurred in patients with AECOPD after their hospital admission and during their hospital stay.

Gene expression profiles of PBMCs were investigated in patients with COPD, compared with healthy controls and correlated with lung function measurement [12]. Differential expression of 45 known genes was identified, of which 16 markers had significant correlation with quantitative traits and differential expression between cases and controls and 2 genes, *RP9* and *NAPE-PLD*, were identified as decreased in patients with COPD, as compared to controls, in both lung tissue and blood. Gene expression profiles of PBMCs were recently identified and validated in smokers with and without COPD and corrected with clinical phenotypes such as sex, age, body mass index, family history, smoking status and pack-years of smoking [25]. Of them, 16 candidate genes were found to be associated with airflow obstruction

**Table 16 Genes downregulated more than fivefold in peripheral blood mononuclear cells of patients with AECOPD<sup>a</sup>**

AE-3 vs AE-1		AE-10 vs AE-1		AE-10 vs AE-3	
Fold changes	Genes	Fold changes	Genes	Fold changes	Genes
5.0	<i>ITGB3</i>	10.2	<i>MPO</i>	10.3	<i>MOXD1</i>
5.1	<i>CGI-69</i>	10.4	<i>LOC653492</i>	10.3	<i>LOC152573</i>
5.2	<i>SPTB</i>	10.5	<i>SPP1</i>	10.7	<i>SPDEF</i>
5.2	<i>BCL2L1</i>	10.6	<i>ANK1</i>	10.8	<i>CCDC80</i>
5.2	<i>GATA1</i>	11.0	<i>DEFA4</i>	11.0	<i>CTSG</i>
5.3	<i>FBXO7</i>	11.0	<i>MOXD1</i>	11.0	<i>CAMP</i>
5.6	<i>SELENBP1</i>	11.0	<i>HIG2</i>	11.3	<i>PLA2G2D</i>
5.8	<i>OSBP2</i>	11.1	<i>OSBP2</i>	11.4	<i>SPP1</i>
5.9	<i>LOC643855</i>	11.2	<i>REXO1L3P</i>	11.6	<i>S100P</i>
6.1	<i>ERAF</i>	11.6	<i>SPDEF</i>	11.7	<i>SLC4A11</i>
6.2	<i>EPB49</i>	12.0	<i>COL1A1</i>	11.8	<i>COL3A1</i>
6.2	<i>MYH9</i>	12.2	<i>BPI</i>	11.8	<i>SPAG4</i>
6.4	<i>ALAS2</i>	12.3	<i>SNCA</i>	12.5	<i>THBS2</i>
7.4	<i>LOC644462</i>	12.3	<i>SLC4A11</i>	12.7	<i>MPO</i>
7.8	<i>GMPR</i>	12.5	<i>COL1A1</i>	13.0	<i>PRTN3</i>
8.1	<i>ANK1</i>	12.6	<i>AZU1</i>	13.2	<i>COL1A1</i>
8.9	<i>BPGM</i>	12.6	<i>ARG1</i>	13.3	<i>ELA2</i>
9.1	<i>FAM46C</i>	13.2	<i>GREM1</i>	14.3	<i>LIF</i>
9.2	<i>LOC643497</i>	13.5	<i>DEFA4</i>	14.4	<i>CEACAM5</i>
9.4	<i>TRIM58</i>	13.5	<i>ELA2</i>	14.6	<i>RNF183</i>
9.4	<i>MBNL3</i>	14.2	<i>CEACAM5</i>	14.9	<i>B3Gn-T6</i>
9.5	<i>EPB49</i>	14.5	<i>ITGA11</i>	15.1	<i>AZU1</i>
9.6	<i>EPB49</i>	15.0	<i>CEACAM8</i>	15.4	<i>ITGA11</i>
9.6	<i>EPB42</i>	15.3	<i>SPTB</i>	15.9	<i>DEFA4</i>
9.7	<i>EPB41</i>	15.6	<i>CEACAM5</i>	16.4	<i>CEACAM5</i>
9.7	<i>SLC14A1</i>	16.6	<i>LIF</i>	17.5	<i>MS4A3</i>
9.9	<i>EPB42</i>	17.1	<i>TRIM58</i>	17.8	<i>ARG1</i>
10.1	<i>SNCA</i>	19.2	<i>THY1</i>	20.4	<i>THY1</i>
13.5	<i>TRIM58</i>	19.5	<i>MS4A3</i>	21.1	<i>MS4A3</i>
19.7	<i>SLC4A1</i>	23.1	<i>TRIM58</i>	22.5	<i>SPP1</i>
20.7	<i>EPB41</i>	24.1	<i>MS4A3</i>	34.4	<i>SFRP2</i>
21.6	<i>CA1</i>	27.1	<i>SFRP2</i>	49.9	<i>PLUNC</i>
		29.9	<i>EPB42</i>	57.1	<i>CALCA</i>
		30.4	<i>SPP1</i>	68.9	<i>CALCA</i>
		41.9	<i>ALAS2</i>	80.4	<i>BPIL1</i>
		43.8	<i>EPB42</i>	93.1	<i>BPIL1</i>
		44.2	<i>CALCA</i>		
		48.5	<i>PLUNC</i>		
		55.5	<i>SLC4A1</i>		
		58.6	<i>CALCA</i>		

**Table 16 Genes downregulated more than fivefold in peripheral blood mononuclear cells of patients with AECOPD<sup>a</sup> (Continued)**

70.0	<i>BPIL1</i>
84.3	<i>BPIL1</i>
109.9	<i>CA1</i>

<sup>a</sup>Data are from patients with acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) after the hospital admission.

and secondary clinical phenotypes, 12 with emphysema, 13 with gas trapping and 8 with distance walked. Both previous studies demonstrated the gene expression profiles of PBMCs from patients with stable COPD and addressed the potential significance of smoking. In the present study, we selected healthy control subjects and patients who were not current smokers and demonstrated gene expression profiles of PBMCs from patients with COPD, including stable COPD and AECOPD. We addressed COPD-specific gene expression profiles that should appear in both stable COPD and COPD exacerbation conditions and found COPD-specific 79 genes were upregulated and 23 genes down-regulated more than fivefold as compared with gene expression in controls. In the present study, we selected consistent up- or downregulated gene expression on days 1, 3 and 10 of AECOPD-specific as compared with gene expression in both healthy controls and patients with stable COPD, as AECOPD-specific gene expression profiles. We found that 58 AECOPD-specific genes were upregulated more than fivefold and 238 genes were downregulated more than twofold, as compared to both control subjects and patients with stable COPD.

Variation of gene expression profiles is dependent upon multiple uncontrollable factors, such as study population, age, history, genetic background and treatment. In addition, gene expression profiles vary between harvested sample types, such as sputum, bronchoalveolar lavage fluid, blood or lung tissues. For example, 102 genes were identified to distinguish between non- or mild emphysema and severe emphysema in lung tissue [15] and to distinguish 70 microRNAs and 2,667 mRNAs between smoking patients with or without COPD [26]. In the present study, we investigated gene expression profiles of PBMCs from control subjects, patients with stable COPD, and patients with AECOPD on day 1, day 3 and day 10 of hospital admission, and we found about 3,000 overexpressed genes and 2,000 downregulated genes in patients with stable COPD or AECOPD, as compared with control subjects. These findings indicate that those COPD-specific genes exist in the stable COPD condition and during acute exacerbations of COPD.

Of the COPD-specific genes we studied, *CEACAM1*, *COL6A3*, *NOL3*, *COL1A2*, *MLPH*, *MUC1*, *P8*, *UNQ473*,

**Table 17 Number and details of co-differentially up- or downregulated genes in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects<sup>a</sup>**

SEQ-ID	Gene name	Full name of gene	Stable vs Con	AE-1 vs Con	AE-3 vs Con	AE-10 vs Con
Unexpressed genes (>10)						
D12502	<i>CEACAM1</i>	Carcinoembryonic antigen-related cell adhesion molecule 1	10.1	83.0	66.5	10.5
NM_004369	<i>COL6A3</i>	Collagen, type VI, $\alpha 3$	10.4	21.0	22.4	10.8
AF064599	<i>NOL3</i>	Nucleolar protein 3 (apoptosis repressor with CARD domain)	12.1	13.6	16.3	11.5
BC042586	<i>COL1A2</i>	Collagen, type I, $\alpha 2$	13.1	72.3	92.9	17.2
BC014473	<i>CEACAM1</i>	Carcinoembryonic antigen-related cell adhesion molecule 1	14.7	101.2	61.0	11.8
AY358857	<i>MLPH</i>	Melanophilin	17.0	10.3	12.8	12.2
AF348143	<i>MUC1</i>	Mucin 1, cell surface-associated	20.0	19.7	20.1	28.6
NM_012385	<i>P8</i>	p8 protein (candidate of metastasis 1)	20.1	19.1	21.3	22.1
BC093946	<i>UNQ473</i>	DMC	20.2	45.9	53.1	24.3
NM_001305	<i>CLDN4</i>	Claudin 4	23.0	34.4	39.1	20.7
NM_002933	<i>RNASE1</i>	Ribonuclease, RNase A family, 1 (pancreatic)	26.9	12.5	15.2	37.2
BC053636	<i>H19</i>	H19, imprinted maternally expressed untranslated mRNA	29.5	37.2	28.0	11.8
BC069423	<i>DEFA1</i>	Defensin, $\alpha 1$	33.0	96.1	86.7	10.2
XM_928349	<i>LOC653600</i>	Similar to neutrophil defensin 1 precursor (HNP-1) (HP-1) (HP1) (defensin, $\alpha 1$ )	43.1	115.8	109.4	12.8
Downregulated genes (>5)						
SEQ-ID	Gene name	Full name of genes	Stable vs Con	AE-1 vs Con	AE-3 vs Con	AE-10 vs Con
M38056	<i>HLA-DOA</i>	Major histocompatibility complex, class II, DO $\alpha$	5.3	5.9	5.6	7.3
AY209188	<i>SAA3P</i>	Serum amyloid A3 pseudogene	5.3	6.7	6.4	11.9
BC069511	<i>UBASH3A</i>	Ubiquitin-associated and SH3 domain-containing, A	5.5	10.4	14.3	6.9
AJ421515	<i>CRTAC1</i>	Cartilage acidic protein 1	5.6	25.4	12.5	11.9
AL133666	<i>EPHA6</i>	EPH receptor A6	5.6	5.8	8.2	5.3
NM_020152	<i>C21orf7</i>	Chromosome 21 open reading frame 7	5.7	8.2	9.7	10.4
XM_089384	<i>TTC24</i>	Tetratricopeptide repeat domain 24	5.8	11.7	12.5	12.7
NM_006850	<i>IL24</i>	Interleukin 24	6.0	6.5	10.7	11.1
AL713701	<i>C21orf7</i>	Chromosome 21 open reading frame 7	6.1	9.5	9.5	10.0
XM_931594	<i>LOC643514</i>	Hypothetical protein LOC643514	6.2	11.4	5.7	7.4
NM_006159	<i>NELL2</i>	NEL-like 2 (chicken)	6.3	11.5	7.3	10.0
NM_002348	<i>LY9</i>	Lymphocyte antigen 9	6.7	8.2	7.4	6.5
XM_934852	<i>LOC129293</i>	Hypothetical protein LOC129293	6.9	14.5	12.9	9.4
BC062589	<i>LY9</i>	Lymphocyte antigen 9	6.9	7.3	7.1	5.5
XM_934149	<i>KIAA0748</i>	KIAA0748	7.0	7.5	11.2	6.2
BC008567	<i>C21orf7</i>	Chromosome 21 open reading frame 7	7.3	6.3	7.5	7.7
NM_138363	<i>CCDC45</i>	Coiled-coil domain containing 45	7.8	6.4	5.9	5.2
BC022101	<i>UNQ470</i>	GAAI470	7.8	44.1	18.1	32.3
BC027920	<i>LY9</i>	Lymphocyte antigen 9	7.9	6.2	5.8	5.3
BC033896	<i>AK5</i>	Adenylate kinase 5	8.2	8.2	10.6	9.9

**Table 17 Number and details of co-differentially up- or downregulated genes in peripheral blood mononuclear cells of patients with stable COPD or AECOPD compared to healthy control subjects<sup>a</sup> (Continued)**

XM_085151	<i>YLPM1</i>	YLP motif containing 1	10.7	8.7	5.1	7.4
NM_014553	<i>TFCP2L1</i>	Transcription factor CP2-like 1	16.1	21.8	32.0	14.9
NM_001007098	<i>SCP2</i>	Sterol carrier protein 2	21.0	27.9	18.7	18.6

<sup>a</sup>Data are from patients with stable chronic obstructive pulmonary disease (stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to healthy controls (Con).

*CLDN4*, *RNASE1*, *H19*, *DEFA1* and *LOC653600* were upregulated more than tenfold, mainly related to nuclear proteins, collagens or molecular structure. We noted that transcription factor CP2 (*TFCP2L1*) and *SCP2* were downregulated more than tenfold. In previous studies, these genes, including *CEACAM1*, *TFCP2L1* and *SCP2*, were not found to be associated with COPD. The *SCP2* gene is located within chromosome 1 and encodes the nonspecific lipid transfer protein *SCP2*, which is involved in organellar fatty acid metabolism [27,28] and the translocation of cytoplasmic free cholesterol

to the mitochondria [29]. Our results indicate that PBMCs from patients with stable COPD or AECOPD had downregulated *SCP2*, which might point to severe metabolic disorder and thus that *SCP2* downregulation might contribute to one of the common comorbidities of COPD [30]. *TFCP2* is a member of a family of transcription factors that regulate genes involved in events from early development to terminal differentiation [31]. PBMCs with downregulated *TFCP2* of patients with COPD might have less capacity of the transcriptional switch of globin gene promoters, many other cellular and

**Table 18 Number of co-differentially up- or downregulated genes in peripheral blood mononuclear cells of patients with AECOPD compared to patients with stable COPD and healthy control subjects<sup>a</sup>**

Fold change	>5	>10
Upregulated	58	8
Fold change	>2	>3
Downregulated	238	8

Selected co-differentially upregulated genes (>10-fold)

SEQ_ID	Gene name	AE-1		AE-3		AE-10	
		AE-1 vs Con	AE-1 vs Stable	AE-3 vs Con	AE-3 vs Stable	AE-10 vs Con	AE-10 vs Stable
BC004490	<i>FOS</i>	27.4	28.6	33.5	34.9	13.2	13.7
BC015492	<i>IFI27</i>	12.3	10.3	13.1	11.0	21.6	18.1
NM_001554	<i>CYR61</i>	12.0	40.3	11.2	37.6	11.7	39.2
NM_001901	<i>CTGF</i>	35.7	26.6	36.9	27.5	59.3	44.2
NM_003979	<i>GPRC5A</i>	21.2	12.6	19.2	11.4	75.8	45.1
NM_006732	<i>FOSB</i>	21.7	13.7	40.1	25.3	35.6	22.5
NM_133504	<i>DCN</i>	19.0	17.2	19.6	17.8	20.0	18.1
XM_373497	<i>LOC387763</i>	41.4	13.5	46.4	15.2	41.3	13.5

Selected co-differentially downregulated genes (>3-fold)

SEQ_ID	Gene names	AE-1		AE-3		AE-10	
		AE-1 vs Con	AE-1 vs Stable	AE-3 vs Con	AE-3 vs Stable	AE-10 vs Con	AE-10 vs Stable
AJ002102	<i>KIR2DS2</i>	3.7	3.8	7.4	7.6	4.2	4.4
BC022407	<i>SH2D1B</i>	3.0	3.7	4.8	5.9	3.1	3.8
BC066595	<i>SH2D1B</i>	3.6	3.2	9.9	8.9	3.6	3.2
BC100911	<i>CD8B</i>	11.2	4.4	16.0	6.3	7.9	3.1
NM_001004698	<i>OR2W5</i>	3.7	3.1	4.7	4.0	3.7	3.1
NM_004931	<i>CD8B</i>	10.3	5.3	11.5	5.9	6.6	3.4
NM_031950	<i>KSP37</i>	4.8	5.0	9.8	10.2	3.0	3.1
NM_201633	<i>TCF7</i>	15.6	5.6	30.4	10.8	8.9	3.2

<sup>a</sup>Data are from acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to patients with stable COPD (Stable) or healthy controls (Con).

**Table 19 Number of genes in peripheral blood mononuclear cells of patients with AECOPD<sup>a</sup>**

	Down-down		Down-up	Up-down	Up-up
Total	353		784	1,005	127
>2-fold	52		131	238	8
>4-fold	3		3	7	0
>5-fold	2		0	0	0
Selected co-differentially expressed genes at the down-down pattern (>4-fold)					
SEQ-ID	Gene name		Full name of gene	AE-3 vs AE-1	AE-10 vs AE-3
NM_000032	<i>ALAS2</i>		Aminolevulinic acid, delta-, synthase 2	6.4	6.5
BC099627	<i>EPB42</i>		Erythrocyte membrane protein band 4.2	9.9	4.4
BC027890	<i>CA1</i>		Carbonic anhydrase I	21.6	5.1
Selected co-differentially expressed genes at the down-up pattern (>4-fold)					
SEQ-ID	Gene name		Full name of gene	AE-3 vs AE-1	AE-10 vs AE-3
AK127453	N/A		Homo sapiens cDNA FLJ45545 fis, clone BRTHA2034281.	4.7	5.7
NM_003944	<i>SELENBP1</i>		Selenium-binding protein 1	5.6	4.1
BC090921	<i>MYH9</i>		Myosin, heavy chain 9, non-muscle	6.2	4.1
Selected co-differentially expressed genes at the up-down pattern (>4-fold)					
SEQ-ID	Gene name		Full name of gene	AE-3 vs AE-1	AE-10 vs AE-3
NM_181717	<i>HCG27</i>		HLA complex group 27	4.1	7.3
NM_177551	<i>GPR109A</i>		G protein-coupled receptor 109A	4.3	7.5
NM_006018	<i>GPR109B</i>		G protein-coupled receptor 109B	4.4	5.1
AF249277	<i>MTHFS</i>		5,10-methenyltetrahydrofolate synthetase (5-formyltetrahydrofolate cyclo-ligase)	4.6	5.3
AY234180	<i>BCL2A1</i>		BCL2-related protein A1	5.2	4.0
BC010952	<i>P3</i>		Peptidase inhibitor 3, skin-derived (SKALP)	6.0	4.4
NM_002243	<i>KCNJ15</i>		Potassium inwardly rectifying channel, subfamily J, member 15	7.0	4.8
Selected co-differentially expressed genes at the up-up pattern (>2-fold)					
SEQ-ID	Gene name		Full name of gene	AE-3 vs AE-1	AE-10 vs AE-3
Z15108	<i>PRKCZ</i>		Protein kinase C, zeta	2.0	2.8
BC037798	<i>CGI-38</i>		Brain-specific protein	2.0	2.4
NM_001033581	<i>PRKCZ</i>		Protein kinase C, zeta	2.1	2.8
NM_007168	<i>ABCA8</i>		ATP-binding cassette, subfamily A, member 8	2.1	4.0
AK022468	<i>SORBS1</i>		Sorbin and SH3 domain containing 1	2.3	3.5
NM_006403	<i>NEDD9</i>		Neural precursor cell expressed, developmentally downregulated 9	2.3	2.2
NM_023037	<i>FRY</i>		Furry homologue ( <i>Drosophila</i> )	2.3	2.1
NM_016730	<i>FOLR1</i>		Folate receptor 1 (adult)	3.0	11.7
Down-down	GENE_NAME	SEQ_ID	AE-1 vs Stable	AE-3 vs Stable	AE-10 vs Stable
	<i>ALAS2</i>	NM_000032	17.64	2.76	-2.37
	<i>EPB42</i>	BC099627	10.02	1.01	-4.37
	<i>CA1</i>	BC027890	103.93	4.81	-1.06
Down-up	GENE_NAME	SEQ_ID	AE-1 vs Stable	AE-3 vs Stable	AE-10 vs Stable
	N/A	AK127453	-1.69	-7.90	-1.38
	<i>SELENBP1</i>	NM_003944	3.97	-1.41	2.92
	<i>MYH9</i>	BC090921	-1.36	-8.40	-2.04

**Table 19 Number of genes in peripheral blood mononuclear cells of patients with AECOPD<sup>a</sup> (Continued)**

	GENE_NAME	SEQ_ID	AE-1 vs Stable	AE-3 vs Stable	AE-10 vs Stable	
Up-down	<i>HCG27</i>	NM_181717	1.09	4.47	-1.63	
	<i>GPR109A</i>	NM_177551	4.12	17.79	2.36	
	<i>GPR109B</i>	NM_006018	2.64	11.64	2.28	
	<i>MTHFS</i>	AF249277	4.51	20.75	3.95	
	<i>BCL2A1</i>	AY234180	2.38	12.45	3.11	
	<i>PI3</i>	BC010952	1.03	6.20	1.42	
	<i>KCNJ15</i>	NM_002243	2.25	15.78	3.26	
	Up-up	<i>PRKCZ</i>	Z15108	-1.25	1.61	4.46
		<i>CGI-38</i>	BC037798	-5.87	-2.86	-1.18
<i>PRKCZ</i>		NM_001033581	-1.61	1.30	3.64	
<i>ABCA8</i>		NM_007168	-1.27	1.68	6.69	
<i>SORBS1</i>		AK022468	1.28	2.92	10.30	
<i>NEDD9</i>		NM_006403	2.43	5.57	12.15	
<i>FRY</i>		NM_023037	-1.11	2.08	4.34	
<i>FOLR1</i>		NM_016730	-4.20	-1.39	8.39	

<sup>a</sup>Data are from acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission. Comparisons are between AE-1 and AE-3 or between AE-3 and AE-10.



viral gene promoters, or interaction with certain inflammatory response factors, although the exact mechanism and pathological role remain unclear.


AECOPD-specific gene expression profiles were selected by comparing them with both healthy control subjects and patients with stable COPD, including 647 upregulated genes and 238 downregulated genes (greater than twofold upregulation). Of them, *FOS*, *IFI27*, *CYR61*, *CTGF*, *GPRC5A*, *FOSB*, *DCN* and *LOC387763* were upregulated more than tenfold and *KIR2DS2*, *SH2D1B*, *CD8B*, *OR2W5*, *KSP37* and *TCF7* were downregulated more than threefold.

We noticed that some genes, such as *FOS*, *CYR61* and *CTGF*, were upregulated in PBMCs from patients with either stable COPD or AECOPD, consistent with the lung tissue gene expression profiles of patients with COPD or smokers, in whom the genes were expressed mainly in alveolar epithelial cells, airway epithelial cells and stromal and inflammatory cells [14]. Other genes, including *GPRC5A*, *LOC387763* and *KIR2DS2*, were not found to be associated with AECOPD in previous publications. *CTGF* is a cysteine-rich peptide implicated in several biological processes, such as cell proliferation, survival and migration, and involved in pulmonary vascular remodeling and hypertension in COPD. It was evidenced by the experimental finding that CTGF short-hairpin RNA could significantly prevent CTGF and cyclin D1 expression, arrest cell cycle at the G<sub>0</sub>/

G<sub>1</sub> phase, suppress cell proliferation in smoking-exposed pulmonary smooth muscle cells and ameliorate pulmonary vascular remodeling [32]. Another study demonstrated that some inflammatory genes (*IL-1 $\beta$* , *IL-6*, *IL-8*, *CCL2* and *CCL8*) were upregulated, whereas some growth factor receptor genes (*BMP2*, *CTGF*, *FGF1*, *KDR* and *TEK*) were downregulated in lung tissue samples from patients who were current smokers or had moderate COPD [33].


Downregulation of *TCF7* was found in PBMCs of patients with COPD and current smoking and was correlated with some clinical phenotypes, such as emphysema, gas trapping and distance walked [25]. In the present study, we also found that *TCF7* was downregulated in ex-smokers with COPD by about an absolute threefold compared with control subjects, and, in patients with AECOPD, *TCF7* was downregulated by about an absolute tenfold compared with both control subjects and patients with stable COPD. These findings indicate that *TCF7* not only is a COPD-specific gene but also is associated with the severity of the disease. *TCF7* is a member of a family of HMG box containing factors associated with  $\beta$ -catenin to mediate Wnt signaling, controls the switch between cell self-renewal and differentiation and plays a role in B cell and T cell development. *TCF7* was found to be the most downregulated transcription factor when CD34+ cells switched into CD34- cells through a coordinated






regulation of the binding between *TCF7* and the short isoforms of *RUNX1* [34]. It is possible the downregulation of *TCF7* and associated regulation may be one part of molecular mechanism of PBMC incapacity during AECOPD.

Dynamic alterations of gene expression profiles in patients with AECOPD were evaluated with dynamic DESS scores. *ALAS2*, *EPB42* and *CA1* were co-differentially expressed with a down-down type in patients with AECOPD. Among these three genes, the *CA1* gene encodes







**Figure 7 Gene expression profile comparisons regarding signaling pathways.** Graphs describe co-differentially upregulated genes (**A**) in different pathways of peripheral blood mononuclear cells from patients with chronic obstructive pulmonary disease (COPD), including patients with stable COPD and acute exacerbation of COPD (AECOPD), as compared to healthy control subjects. Also shown are co-differentially expressed upregulated genes (**B**) or downregulated genes (**C**) from patients with AECOPD, as compared to patients with stable COPD and healthy control subjects. ECM, Extracellular matrix; MHC, Major histocompatibility complex; Pi3K, Phosphatidylinositol 3-kinase.

a protein which is important in respiratory function, fluid secretion and maintenance of cellular acid–base homeostasis [35]. The genes with a down–up type included *SELENBP1*, *MYH9* and an unnamed gene in chromosome 19, both of which are associated with psychotic disorders [36,37]. One limitation of the present study is the small sample size, which detracts from the generalizability of the results presented.

### Conclusions

Dynamic alterations of PBMC gene expression profiles were initially investigated in patients with AECOPD, as compared with healthy control subjects or patients with stable COPD. A panel of genes, including eight that were upregulated and eight that were downregulated, were recommended as AECOPD-specific dynamic biomarkers. AECOPD-specific up- or downregulated genes in the biological process, cellular components or molecular function were defined and

participated in complement and coagulation cascades, infection, antigen processing and presentation, natural killer cell–mediated cytotoxicity, and/or cancer-causing potential. The integration of dynamic bioinformatics with clinical phenotypes helped us to identify and validate AECOPD-specific biomarkers to help define the severity, duration and response of the disease to therapies.

### Key messages

- Circulating dynamic biomarkers were identified for the specificity and severity of AECOPD.
- A panel of 16 genes were selected as AECOPD-specific biomarkers.
- This is an initial study designed to examine gene expression profiles of peripheral blood mononuclear cells and identify dynamic changes of AECOPD-specific biomarkers.

## Additional files

**Additional file 1: DESS scores.** This file lists Digital Evaluation Score System (DESS) scores of subjects from each group.

**Additional file 2: Eight supplemental figures. Figure S1.** A box plot showing distributions of log<sub>2</sub> ratios among groups. They reflect our assessment of the quality of genetic data after the filtering and distribution of data sets. **Figure S2.** Hierarchical clustering shows distinguishable gene expression profiles and relationships between different groups. **Figure S3.** Co-differentially upregulated genes within 10 comparison pairs mainly involved in the biological process. **Figure S4.** Co-differentially downregulated genes within 10 comparison pairs mainly involved in the biological process. **Figure S5.** Co-differentially upregulated genes within 10 comparison pairs mainly involved in the cellular component. **Figure S6.** Co-differentially downregulated genes within 10 comparison pairs mainly involved in the cellular component. **Figure S7.** Co-differentially upregulated genes within 10 comparison pairs mainly involved in the molecular function. **Figure S8.** Co-differentially downregulated genes within 10 comparison pairs mainly involved in the molecular function.

**Additional file 3: Differentially expressed genes.** This file lists 10 comparison pairs with information of fold changes and regulation, normalized intensities or annotations.

**Additional file 4: Co-differentially expressed genes.** This file lists COPD-specific and AECOPD-specific genes, as well as dynamically changed genes, in patients with AECOPD.

**Additional file 5: Gene Ontology database.** This file lists gene numbers for 10 comparison pairs with certain GO (Gene Ontology) terms and different enrichment score ranges.

## Abbreviations

AE-1: Acute exacerbations of chronic obstructive pulmonary disease on day 1; AE-3: Acute exacerbations of chronic obstructive pulmonary disease on day 3; AE-10: Acute exacerbations of chronic obstructive pulmonary disease on day 10; AECOPD: Acute exacerbation of chronic obstructive pulmonary disease; ALAS2: Aminolevulinic acid synthase 2; CA1: Carbonic anhydrase I; COPD: Chronic obstructive pulmonary disease; CXCL8: Chemokine (C-X-C motif) ligand 8; DESS: Digital evaluation score system; EPB42: Erythrocyte membrane protein band 4.2; FEV<sub>1</sub>: Forced expiratory volume in 1 second; FVC: Forced vital capacity; GO: Gene Ontology; IL: Interleukin; MHC: Major histocompatibility complex; MYH9: Myosin, heavy polypeptide 9, non-muscle; PBMC: Peripheral blood mononuclear cell; SCP2: Sterol carrier protein 2; SELENBP1: Selenium-binding protein 1; TCF7: Transcription factor 7; TFCEP2L1: Transcription factor CP2-like 1.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

XW carried out the study, participated in the data analysis and drafted the manuscript. XRS participated in the data mining and analysis. CSC and CXB participated in the study design and data analysis and helped to revise the manuscript. XDW conceived of the study, participated in its design and coordination and finalized the manuscript. All authors read and approved the final manuscript.

## Acknowledgements

The work was supported by Shanghai Leading Academic Discipline Project (project B115), Zhongshan Distinguished Professor Grant (to XDW), the National Nature Science Foundation of China (91230204, 81270099, 81320108001, 81270131, 81300010), the Shanghai Committee of Science and Technology (12JC1402200, 12431900207, 11410708600), the Zhejiang Provincial Natural Science Foundation (Z2080988), the Zhejiang Provincial Science Technology Department Foundation (2010C14011) and the Ministry of Education, Academic Special Science and Research Foundation for PhD Education (20130071110043).

## Author details

<sup>1</sup>Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Fenglin Rd. No180, 200032, Shanghai, China. <sup>2</sup>Department of Respiratory Medicine, Wenzhou Medical University and The First Hospital, Nanbaixiang, 325000, Wenzhou, China. <sup>3</sup>Shanghai Institute of Clinical Bioinformatics, Fudan University Center for Clinical Bioinformatics, Shanghai Respiratory Research Medicine, Fenglin Rd. No 180, 200032, Shanghai, China.

Received: 28 April 2014 Accepted: 26 August 2014

Published online: 19 November 2014

## References

- Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S, Meek P, Martinez F, McNicholas W, Muris J, Austegard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tjep B, Vestbo J, Wouters E, ZuWallack R: **Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.** *Eur Respir J* 2004, **23**:932–946.
- Pauwels RA, Rabe KF: **Burden and clinical features of chronic obstructive pulmonary disease (COPD).** *Lancet* 2004, **364**:613–620.
- Fang X, Wang X, Bai C: **COPD in China: the burden and importance of proper management.** *Chest* 2011, **139**:920–929.
- Celli BR, Barnes PJ: **Exacerbations of chronic obstructive pulmonary disease.** *Eur Respir J* 2007, **29**:1224–1238. A published erratum appears in *Eur Respir J* 2007, **30**:401.
- Donaldson GC, Seemungal TA, Patel IS, Lloyd-Owen SJ, Wilkinson TM, Wedzicha JA: **Longitudinal changes in the nature, severity and frequency of COPD exacerbations.** *Eur Respir J* 2003, **22**:931–936.
- Murtagh E, Heaney L, Gingles J, Shepherd R, Kee F, Patterson C, MacMahon J: **Prevalence of obstructive lung disease in a general population sample: the NICECOPD study.** *Eur J Epidemiol* 2005, **20**:443–453.
- Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA: **Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.** *Am J Respir Crit Care Med* 2000, **161**:1608–1613.
- Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Paré PD: **The nature of small-airway obstruction in chronic obstructive pulmonary disease.** *N Engl J Med* 2004, **350**:2645–2653.
- Barnes PJ, Shapiro SD, Pauwels RA: **Chronic obstructive pulmonary disease: molecular and cellular mechanisms.** *Eur Respir J* 2003, **22**:672–688.
- Melguizo C, Prados J, Luque R, Ortiz R, Rama AR, Caba O, Rodríguez-Serrano F, Álvarez PJ, Aránega A: **Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance.** *Cancer Chemother Pharmacol* 2013, **71**:537–541.
- Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, De Souza MM, Vessey R, Celli B: **Profiling serum biomarkers in patients with COPD: associations with clinical parameters.** *Thorax* 2007, **62**:595–601.
- Bhattacharya S, Tyagi S, Srisuma S, Demeo DL, Shapiro SD, Bueno R, Silverman EK, Reilly JJ, Mariani TJ: **Peripheral blood gene expression profiles in COPD subjects.** *J Clin Bioinforma* 2011, **1**:12.
- Golpon HA, Coldren CD, Zamora MR, Cosgrove GP, Moore MD, Tuder RM, Geraci MW, Voelkel NF: **Emphysema lung tissue gene expression profiling.** *Am J Respir Cell Mol Biol* 2004, **31**:595–600.
- Ning W, Li CJ, Kaminski N, Feghali-Bostwick CA, Alber SM, Di YP, Otterbein SL, Song R, Hayashi S, Zhou Z, Pinsky DJ, Watkins SC, Pilewski JM, Sciurba FC, Peters DG, Hogg JC, Choi AM: **Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease.** *Proc Natl Acad Sci U S A* 2004, **101**:14895–14900.
- Spira A, Beane J, Pinto-Plata V, Kadar A, Liu G, Shah V, Celli B, Brody JS: **Gene expression profiling of human lung tissue from smokers with severe emphysema.** *Am J Respir Cell Mol Biol* 2004, **31**:601–610.
- Wang X, Liotta L: **Clinical bioinformatics: a new emerging science.** *J Clin Bioinforma* 2011, **1**:1.
- Wang X: **Role of clinical bioinformatics in the development of network-based Biomarkers.** *J Clin Bioinforma* 2011, **1**:28.
- Chen H, Wang X: **Significance of bioinformatics in research of chronic obstructive pulmonary disease.** *J Clin Bioinforma* 2011, **1**:35.
- Rodríguez-Roisin R: **Toward a consensus definition for COPD exacerbations.** *Chest* 2000, **117**(5 Suppl 2):398S–401S.

20. Chen H, Song Z, Qian M, Bai C, Wang X: Selection of disease-specific biomarkers by integrating inflammatory mediators with clinical informatics in AECOPD patients: a preliminary study. *J Cell Mol Med* 2012, **16**:1286–1297.
21. Wang X, Wu X: Expression analysis of stable chronic obstructive pulmonary disease and acute exacerbation of chronic obstructive pulmonary disease. [http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE60399] (published 14 August 2014).
22. Rupp J, Kothe H, Mueller A, Maass M, Dalhoff K: Imbalanced secretion of IL-1 $\beta$  and IL-1RA in *Chlamydia pneumoniae*-infected mononuclear cells from COPD patients. *Eur Respir J* 2003, **22**:274–279.
23. To M, Yamamura S, Akashi K, Charron CE, Barnes PJ, Ito K: Defect of adaptation to hypoxia in patients with COPD due to reduction of histone deacetylase 7. *Chest* 2012, **141**:1233–1242.
24. Ngkelo A, Meja K, Yeadon M, Adcock I, Kirkham PA: LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and G $\alpha$  dependent PI-3kinase signalling. *J Inflamm (Lond)* 2012, **9**:1.
25. Bahr TM, Hughes GJ, Armstrong M, Reisdorph R, Coldren CD, Edwards MG, Schnell C, Kedi R, LaFlamme DJ, Reisdorph N, Kechris KJ, Bowler RP: Peripheral blood mononuclear cell gene expression in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2013, **49**:316–323.
26. Ezzie ME, Crawford M, Cho JH, Orellana R, Zhang S, Gelinis R, Batte K, Yu L, Nuovo G, Galas D, Diaz P, Wang K, Nana-Sinkam SP: Gene expression networks in COPD: microRNA and mRNA regulation. *Thorax* 2012, **67**:122–131.
27. Szulakowski P, Crowther AJ, Jiménez LA, Donaldson K, Mayer R, Leonard TB, MacNee W, Drost EM: The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006, **174**:41–50.
28. Morris HR, Larsen BS, Billheimer JT: A mass spectrometric study of the structure of sterol carrier protein SCP<sub>2</sub> from rat liver. *Biochem Biophys Res Commun* 1988, **154**:476–482.
29. Yanase T, Hara T, Sakai Y, Takayanagi R, Nawata H: Expression of sterol carrier protein 2 (SCP2) in human adrenocortical tissue. *Eur J Endocrinol* 1996, **134**:501–507.
30. Mannino DM, Thorn D, Swensen A, Holguin F: Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur Respir J* 2008, **32**:962–969.
31. Swendeman SL, Spielholz C, Jenkins NA, Gilbert DJ, Copeland NG, Sheffery M: Characterization of the genomic structure, chromosomal location, promoter, and development expression of the  $\alpha$ -globin transcription factor CP2. *J Biol Chem* 1994, **269**:11663–11671.
32. Wang R, Xu YJ, Liu XS, Zeng DX, Xiang M: Knockdown of connective tissue growth factor by plasmid-based short hairpin RNA prevented pulmonary vascular remodeling in cigarette smoke-exposed rats. *Arch Biochem Biophys* 2011, **508**:93–100.
33. Llinàs L, Peinado VI, Goñi JR, Rabinovich R, Pizarro S, Rodríguez-Roisin R, Barberà JA, Bastos R: Similar gene expression profiles in smokers and patients with moderate COPD. *Pulm Pharmacol Ther* 2011, **24**:32–41.
34. Wu JQ, Seay M, Schulz VP, Hariharan M, Tuck D, Lian J, Du J, Shi M, Ye Z, Gerstein M, Snyder MP, Weissman S: Tcf7 is an important regulator of the switch of self-renewal and differentiation in a multipotential hematopoietic cell line. *PLoS Genet* 2012, **8**:e1002565.
35. Davis MB, West LF, Barlow JH, Butterworth PH, Lloyd JC, Edwards YH: Regional localization of carbonic anhydrase genes CA1 and CA3 on human chromosome 8. *Somat Cell Mol Genet* 1987, **13**:173–178.
36. Amar S, Ovadia O, Maier W, Ebstein R, Belmaker RH, Mishmar D, Agam G: Copy number variation of the SELENBP1 gene in schizophrenia. *Behav Brain Funct* 2010, **6**:40.
37. Kanazawa T, Chana G, Glatt SJ, Mizuno H, Masliah E, Yoneda H, Tsuang MT, Everall IP: The utility of SELENBP1 gene expression as a biomarker for major psychotic disorders: replication in schizophrenia and extension to bipolar disorder with psychosis. *Am J Med Genet B Neuropsychiatr Genet* 2008, **147B**:686–689.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

